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1 Introduction
1.1 Human Glioblastoma multiforme
Glioblastoma multiforme (GBM) is the most common adult glioma with a medium
overall survival (MOS) of 15 months (450 days) (Hau et al., 2007). The incidence
of GBM in the USA is 3.19 in 1000000 (Vigneswaran et al., 2015). The median age
at diagnosis is 64 years. Men are 1.6 times more often aﬀected than women (Ver-
haak et al., 2010). The reason for this gender-speciﬁc preponderance is unclear.
95% of all GBM develop de novo (primary glioblastoma multiforme, PGBM), while
5% evolve out of low grade gliomas, for example astrocytomas, and are named sec-
ondary glioblastoma multiforme (SGBM) (Figure 1.1). Analysis of GBM genomics
revealed multiple tumour suppressor and oncogenes that are inactive and active,
respectively, during tumour progression and de novo formation (Figure 1.2). For
example, in low grade gliomas and SGBM, mutations of isocitrate dehydrogenase
(IDH1 and IDH2) are found most frequently, whereas PGBM never have these muta-
tions. Genetic diﬀerences between SGBM and PGBM tumours are used in diagnostics
(Nobusawa et al., 2009) and are relevant for the selection of the therapy. With im-
munohistochemistry (IHC), the expression of IDH1 in SGBM and low grade GBM can
be detected easily (Figure 1.3).
Despite various eﬀorts and combined therapy (Hau et al., 2007; Stupp et al., 2009),
PGBM is still an incurable disease. At the moment, the standard therapy for patients
(a) T1 sequence PGBM with
contrast agent
(b) T2 sequence PGBM
Figure 1.1: Magnetic resonance imaging from a PGBM patient, transversal sections.
Tumour in the right hemisphere.
1
1 Introduction
???????????????????
????
Diffuse Astrocytoma
WHO II
Anaplastc
Astrocytoma   
WHO III
????????????????
??????
??????????
????????????????
???????
?????????
?????????????
??????
?????????????????
??????
??????????
?????????????????
???????
??? ????
????????????
??????
?????????
???????
??????
??????
???????
?????????
???????
IDH wild
type
IDH 
mutated
Figure 1.2: Development of PGBM and SGBM. IDH mutation as diﬀerence of low
grade, SGBM and PGBM.
(a) IDH1 positive sample of SGBM patient (b) IDH1 negative sample of PGBM patient
Figure 1.3: IHC, 200 x, IDH1. a) secondary glioblastoma multiforme, positive for the
R132H point mutation, b) primary glioblastoma multiforme, negative for the R132H
point mutation. Used for diagnosis of PGBM and SGBM.
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below the age of 70 years consists of: surgical resection, external beam irradiation
ﬁve times a week for six weeks, as well as oral temozolomide (TMZ) daily. Relapse
occurs frequently within approximately 7 months (210 days) (Aliﬁeris and Trafalis,
2015) (Figure 1.4). This is due to the fact that a complete microscopic resection can
never be achieved because of the diﬀuse inﬁltration of PGBM. If re-irradiation and
re-resection of recurrent tumours are not eligible, other medications like carboplatin,
irinotecan, carmustine, etoposide, or vincristine are used in clinical trials (Mrugala
et al., 2012; Pallud et al., 2015). Even investigatory approaches like convection
enhanced delivery, stem cell treatment, immunotherapy, and gene therapy might
be available in the future to elongate the survival of PGBM patients (Arshad et al.,
2015; Stangeland et al., 2015).
For the choice of medication, it is essential to have prognostic markers to predict
the course of the disease, or to evaluate developed medications. At the moment there
is only one stable predictive marker deﬁned for PGBM therapy. The success of PGBM
treatment with TMZ is depends on the methylation status of the O6-methylguanine
DNA methyltransferase (MGMT) promoter (Hegi et al., 2008; Quillien et al., 2012;
Stupp et al., 2009). TMZ is an alkylating agent, targeting the O6-position of guanine.
This leads to DNA double strand breaks and ﬁnally results in apoptosis. MGMT,
however, removes methyl adducts at the O6-guanine and works therefore as a DNA
repair enzyme, antagonising TMZ. If the MGMT promoter is methylated, the enzyme
is not produced and the alkylating agents can lead to DNA double strand breaks
(Hegi et al., 2004). Patients with a high MGMT promoter methylation beneﬁt more
from a TMZ therapy and have a longer MOS than patients with low MGMT promoter
methylation.
Histopathologically, PGBM are very heterogeneous (Bonavia et al., 2011). Mod-
ern pathology combines morphological patterns with molecular markers to manifest
(a) prae operation (b) post operation (c) secondary PGBM
Figure 1.4: Magnetic resonance imaging from a PGBM patient, sagittal sections.
a) before surgical resection, b) after surgical resection, c) 4 months after surgical
resection, secondary PGBM visible.
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diagnosis. However, PGBM grow inﬁltrative, lead to neovascularisation and necrosis,
and show an enhanced mitotic activity and nuclear atypia (Vigneswaran et al., 2015)
The tumour is usually surrounded by peritumoural edema and inﬂammation. Histo-
logical variants are: small cell PGBM, giant cell PGBM (Figure 1.5), and gliosarcomas
(Louis et al., 2007).
Guan et al. (2014) and the National Human Genome Research Institute (USA)
distinguish on the basis of expression proﬁling between classical, proneural (PN),
mesenchymal (MES), and neural PGBM subtypes. There are other subclassiﬁcation
schemes such as Mao et al. (2013) who deﬁne only two subtypes, PN and MES
PGBM. Although the exact number of subtypes is controversial, there is always an
undisputed clear diﬀerentiation between PN and MES. MES are more resistant to
radiotherapy than PN, which leads to a shorter MOS of patients with MES PGBM
(Figure 1.6). As a possible reason for this diﬀerence, Mao et al. (2013) suggest a
high expression level of genes responsible for DNA repair in MES PGBM. A summary
of subtype speciﬁc markers can be found in Table 1.1. Verhaak et al. (2010) found,
furthermore, that the subtypes MES and PN occur in at least twice as many men as
women. A reason for this sex predominance has still not been found.
As it is still unclear how many subtypes of PGBM can be distinguished and little
is known about the therapeutic advantages of speciﬁc types, there is a need to
understand more about PGBM, especially about markers predictive for successful
therapy and MOS. In addition to research on human material, there is a need
for accurate and reproducible PGBM brain tumour animal models which should be
ideally close to the human cancer. This includes kinetics and anti-tumour immune
responses.
1.2 Models in GBM reasearch
In cancer research a reliable model to investigate tumour growth, cell behaviour,
and to test new therapies is a key to understand more about cancer and to be able
Figure 1.5: H&E, 200x. Example of histopathological PGBM variant: giant cell PGBM
of patient No.47.
4
1 Introduction
(a) MES PGBM (b) PN PGBM
Figure 1.6: H&E, 200 x. Staining of PGBM subtypes: a) MES and b) PN. Subtypes of
PGBM can be deﬁned by genomic analysis or histopathological pattern.
Table 1.1: Subtypes of PGBM, modiﬁed after Mao et al. (2013) and Bhat et al. (2013).
Characteristics PN MES
frequency 60% 40%
sensitivity to therapy relatively sensitive to
radiation
radio resistant
stem cell markers CD133, CD15 ALDH1A3
potential cell of origin embryonic neonatal
neural stem cell
adult neural stem cell
diﬀerentiated astrocyte
altered signalling pathway Notch, PDGFRA,
GLUT3 mediated
glucose uptake
NF-κB, ALDH1A3,
glycolysis,
inﬂammasome
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to improve patients live.
1.2.1 Mouse models in GBM research
Rodent models have been used for more than 30 years to investigate glioma mor-
phology and to test preclinical therapies. It is common to implant human GBM cells
subcutaneously or intracranially (xenograft model) into an immunocompromised
mouse. These models are used for therapeutic preclinical trials to study for example
angiogenesis, or invasion (Becker et al., 2015; Schmidt et al., 2004; Sun et al., 2015;
Suzuki et al., 2014). For GBM immunotherapy trials syngeneic mouse models are
used (Belcaid et al., 2014).
Histopathological features of mouse GBM models are (Candolﬁ et al., 2007): in-
ﬂammation, hypercellularity, pleomorphism, nuclear atypia, and neovascularisation.
In syngeneic GBM models in contrast to xenograft models you can ﬁnd furthermore
necrosis, hemmorraghes, and pseudopalisading. Invasion of GBM cells into surround-
ing tissue is dependent on the chosen cell line.
Both GBM models stand out because of their high reproducibility, fast in vivo
and ex vivo growth of tumours, and low costs. However, they do not ﬁt for all
experiments. Two of the widely used models in research are: the xenograft model
with human U87-MG GBM cell line and the syngeneic model with the murine cells
Gl261.
The human PGBM cell line U87-MG was isolated in 1966 from a 44 years old male
patient. Gl261 cells were induced by methylcholanthrene in 1970s and serially im-
planted by Ausman et al. (1970). Gl261 tumours resemble ependymoblastom (a
tumour of the central nervous system of embryos) in histology, but closely mimic
GBM phenotypes (Ausman et al., 1970). For example, they are positive for several
GBM markers as vimentin and harbor mutations of the K-ras oncogene and p53 tu-
mour suppressor gene (Szatmári et al., 2006). They grow invasively but will never
metastasize. One advantage compared to other syngeneic models is that they never
spontaneously regress (Vince et al., 2004). A characterisation of growth pattern was
done by Szatmári et al. (2006).
A diﬀerent approach using genetic engineering makes it possible to study tumour
growth in mice with constitutive or conditional alleles of genes associated with GBM
development and are summarized by Weiss et al. (2002).
The choice of the right model is not always easy. This thesis is going to compare
two models in terms of suitability for ALDH research (Section 4.2).
1.2.2 Canine Glioblastoma multiforme
Not only in humans but also in dogs, GBM occur spontaneously and are one of the
most common neoplasms of the canine central nervous system (Stoica et al., 2009).
However, these tumours are very rare. Song et al. (2013) analysed necropsies and
found a prevalence of 2-4% for GBM. A therapy consisting out of resection, radio-,
and chemotherapy like in humans is uncommon. Clinical signs and prognosis of
6
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dogs with GBM are quite similar to the ones of human PGBM patients (Candolﬁ
et al., 2007), with a MOS of 176 days. Neuroimaging features of canine GBM seen in
magnetic resonance imaging correlate well with human PGBM.
The canine GBM are common in brachycephalic breeds, in particular in Boxers
and Boston Terriers (Beveridge and Sobin, 1974; Snyder et al., 2006). GBM are also
found in cattle and pigs. Unlike as described in man, no sex predilection is found
in dogs (Hayes et al., 1975). Many GBM of dogs occur in the subependymal plate
(Palmer, 1976). The growth pattern and the heterogenous histology of canine GBM
is quite similar to human PGBM. They are highly cellular, round in shape, and
the nuclei are rich in chromatin and irregular in shape (Candolﬁ et al., 2007). The
cells are often arranged in rows or in semicircles. The tumours grow inﬁltrative, are
leading to neovascularisation, and show extensive mucinous degeneration and cyst
formation. Necrosis is also found regularly (Beveridge and Sobin, 1974).
1.3 Theory of cancer growth
In general, cancer occurs, when the carefully controlled processes of cell growth and
repair fall out of line. When cells divide in an uncontrolled way and form abnormal
masses of cells, they are called cancer. The cause of this event are gene mutations.
Mutations accumulate over time in our cells while they divide and age. In the end,
certain combinations of mutations can lead to cancer.
Tumours consist of a mixture of diﬀerent cell types. There are two main theories
trying to explain how cancer grows and why cancer is heterogeneous: the stochastic
model and the cancer stem cell (CSC) theory of cancer growth (López-Lázaro, 2015)
(Figure 1.7).
The stochastic model suggests that every single tumour cell can function as a
tumour founding cell. Tumour cells keep their ability to grow and divide although
they diﬀerentiate. Any cell can contributes to the tumour growth because they all
have the same intrinsic potential.
The CSC theory postulates that only a small subpopulation of the tumour cells can
sustain the growth and proliferation of neoplastic clones. This model presumes that
tumours are a well organised system with CSC giving rise to transient amplifying
cells which form the majority of the tumour. Transient amplifying cells can divide
a certain number of times and then become diﬀerentiated cells loosing the ability to
further divide.
There is no real proof in favour of either the theories. But since some cancer
entities reoccur, it is widely accepted, that a particular subpopulation of tumour
cells is not aﬀected by conventional therapies and form new tumours. These cells
are commonly called CSC or tumour initiating cells. Their presence has now been
described in most cancers and is deﬁned by two main characteristics: enhanced
tumourigenicity, and capacity for self-renewal (Dalerba et al., 2007). These ﬁndings
ﬁt best with the CSC theory. Identiﬁcation of the CSC population usually uses cell
surface markers known from corresponding stem cell markers of the tissue of the
7
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Figure 1.7: Models of cancer growth: CSC theory and stochastic model. Heterogene-
ity is maintained in both models.
tumour origin. Nevertheless, not all CSC are identiﬁed by such markers. Therefore,
cells that might be considered as CSC need to show following abilities: giving rise to
experimental tumours after xenotransplantation, recapitulate the tumour of origin
morphologically and immunophenothypically, and allow serial xenotransplantation
(Park et al., 2009). Important markers which are believed to detect CSC are: CD34,
CD38, and aldehyde dehydrogenase 1 (ALDH1) (Choi et al., 2014; Raha et al., 2014).
Recently, ALDH activity has been claimed as a marker for CSC in various organs like
breast (Ginestier et al., 2007; Liu et al., 2014b), colon (Huang et al., 2009), bladder
(Xu et al., 2015a), prostate (Li et al., 2010), and brain (Ni et al., 2015; Schäfer et al.,
2012). When Ginestier et al. (2007) experimentally eliminated ALDH1 in mammary
CSC, growth is inhibited and cells are sensitized to chemotherapy. The role of ALDH
enzymes will be described in detail in Section 1.4.
Resistance of GBM CSC to currently used chemotherapy like temozolomide, car-
boplation, etopsode, and others, is believed to be the major contributing factor in
cancer recurrence and metastasis development. A therapy that kills CSC or induces
diﬀerentiation and shrinks tumours, would possible cure patients. There are several
suggested mechanisms how these cells escape chemo- and radiotherapy. The most
important properties of CSC are: slow growth, increased activation of DNA damage
repair enzymes (Bao et al., 2006; Singh et al., 2003), enhanced expression of eﬄux
transporters, and overexpression of proteins which protect the cell from the toxic
eﬀects of elevated levels of reactive oxygen species, like ALDH1 (Hilton, 1984; Raha
et al., 2014) (Figure 1.8).
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Figure 1.8: Schemes of the role of ALDH in the retionoic acid signaling (RAS) pathway
and as a protective enzyme of reactive oxygen species. a) Retinol is oxidized by the
retinol dehydrogenase to retinal. Retinal is the substrate of ALDH and is converted
to retionoic acid (RA). RA acts on the heterodimer RAR and RXR in the nucleus.
The RAR/ RXR complex regulates the expression of genes which are involved in
cell diﬀerentiation, cell cycle arrest and apoptosis. RAR: retionoic acid receptor,
RXR: retinoid “X” receptor. b) Oxidative stress increases reactive oxygen species in
the tissue. They lead to lipid peroxidation and an increase of aldehydes. ALDH can
catalyse the further oxidation to acids. If ALDH is blocked by any therapeutic agent,
the increase of aldehydes leads to DNA damage and as a consequence to apoptosis.
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1.4 Aldehyde dehydrogenase superfamily
The aldehyde dehydrogenase superfamily is a group of enzymes that catalyse the
dehydrogenation of aldehydes and is preserved in all three taxonomic domains ar-
chaea, bacteria, and eukarya (Jackson et al., 2011). In mammals, ALDH enzymes of
the same isotype are conserved up to 98% on the amino acids sequence level.
Nineteen putatively diﬀerent ALDH in 11 families and 4 subfamilies (Jackson et al.,
2011; Ma and Allan, 2011; Vasiliou and Nebert, 2005) are known at the moment.
This classiﬁcation is based on the percentage of amino acid sequence identity between
the enzymes (Marchitti et al., 2008; Vasiliou and Nebert, 2005). Proteins which are
more than 40% identical are assigned to a particular family, whereas proteins sharing
more than 60% amino acid identity are grouped into one subfamily (Vasiliou and
Nebert, 2005).
In general, the ALDH enzymes catalyse nicotinamide adenine dinucleotide (NAD)
dependent irreversible oxidation of a wide spectrum of endogenous and exogenous
aldehydes (Marchitti et al., 2008). The ALDH proteins can be found in all cellular
compartments (Marchitti et al., 2008) and have a wide tissue distribution. Nor-
mally, aldehydes arise from oxidative degradation of membrane lipids, amino acids,
carbohydrates, and from neurotransmitter catabolism (Marcato et al., 2015). The
isoforms ALDH1A1, ALDH1A2, ALDH1A3, and ALDH8A1 play a major role in retionoic
acid signaling (RAS) (Figure 1.8). Retionoic acid (RA) is produced by oxidation of
all-trans-retinal and 9-cis-retinal (Lane and Bailey, 2005; Raha et al., 2014), which
is catalysed by the before named isoforms. This signal pathway has been identiﬁed
as a important pathway for breast CSC (Ginestier et al., 2009). The gene transcrip-
tion is induced by RA (Campos et al., 2011), and thus ALDH modulates a variety
of biological processes like cell proliferation, diﬀerentiation, cell cycle arrest, and
apoptosis (Muramoto et al., 2010; Raha et al., 2014). ALDH1 positive CSC are also
more tolerant to drugs than ALDH1 negative CSC (Raha et al., 2014), due to the
ability to keep the level of reactive oxygen species (ROS) suﬃciently low to prevent
apoptosis (Figure 1.8). ROS usually emerge from extrinsic and intrinsic stresses.
These stresses inﬂuence the tumour cells all the time.
1.4.1 ALDH1A1
The gene for ALDH1A1 is located at 9q21.13 and is involved in multiple biologi-
cal processes, for example: oxidative stress response (Marchitti et al., 2008), cell
diﬀerentiation (Chute et al., 2006) and drug resistance (Hilton, 1984; Muramoto
et al., 2010). The loss of ALDH1A1 is usually associated with alcohol intolerance.
The ALDH1A1 enzyme can be found in the cytosol of several organs like lung, liver,
breast, brain, and pancreas. Rasper et al. (2010) introduced ALDH1A1 as a novel
maker for PGBM cells with CSC characteristics. There is evidence that ALDH1A1
could be a prognostic marker for PGBM patients, but not to which extent (Adam
et al., 2012; Schäfer et al., 2012). In other tumours like colon carcinoma and prostate
cancer the isotype ALDH1A1 was correlated to poor clinical prognosis (Huang et al.,
10
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2009; Li et al., 2010). In breast CSC, there is recently a shift in scientiﬁc opinion,
whereas till 2011 it was believed that ALDH1A1 is predictive of metastasis, Marcato
et al. (2011b) showed now, that ALDH1A3 is a more reliable marker.
1.4.2 ALDH1A3
The gene of ALDH1A3 is located at 15p26.2. The enzyme catalyses the conversion
of acetate from acetaldehyde (Nakano, 2014). It can be found in the cytosol of
the cells in many organs, like skeletal muscle, lung, breast, brain, liver, and kidney.
Homozygous loss of the ALDH1A3 leads to anophtalmia or microphtalmia and is
autosomal recessive. An experimental inactivation of ALDH1A3 leads to perinatal
death due to nasal defects (Dupé et al., 2003).
In PGBM, there is evidence that ALDH1A3 activity is increased in MES PGBM but
not in PN PGBM (Mao et al., 2013; Nakano, 2014) and contributes to the radiore-
sistance of MES PGBM. Experimental inhibition of ALDH1A3 by short hairpin RNA
mediated gene silencing attenuates not only MES gene signature but also the in vitro
growth and radioresistance (Nakano, 2014). Nakano (2014) and Ni et al. (2015)
describe, that an increased proportion of ALDH1A3 positive cells correlates with ma-
lignancy of glioma and poor MOS of patients.
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GBM is one of the devastating diseases in men. Medium overall survival of PGBM pa-
tients is, though aggressive therapy, approximately 15 months. Rarely full resection
is archived and tumour reoccur regularly after 7 months. A therapy resistent sub-
population of cells might be responsible for tumour re-growth. Reliable predictive
markers and targets for PGBM therapy have yet not been found.
As described in Section 1.4, the protein expression of ALDH1A1 and ALDH1A3 are
of special interest as a prognostic marker for human PGBM patients. The role of
the ALDH superfamily in human PGBM and especially ALDH1 isoforms is re-evaluate
(Section 4.1). A clear correlation between ALDH isoform expression and MOS of
human PGBM patients, will make the inhibition of the enzyme activity interesting
for targeted therapy. To assess which mouse PGBM model would be the best for
ALDH enzyme activity measurements and inhibition, two diﬀerent approaches are
analysed and compared to cell culture conditions and PGBM patients material. In
Section 4.2, a xenograft model and a syngeneic model will be studied.
12
3 Materials and Methods
3.1 Material
The statistical analysis was done with R 3.1.2 with the packages survival (version
2.38-3), tikzDevice (version 0.10-1), DBI (version 0.3.1). Pictures were arranged with
GIMP 2 and Aperior ImageScope (v12.1.0.5029). Survival analysis was done with
Kaplan-Meier estimator and Cox regression test. Used reagents and chemicals and
technical devices can be found in Tables 3.1 and 3.2.
Table 3.1: Chemicals and reagents
Substances Producer
25 bp DNA Ladder Invitrogen™, Life Technologies Corp.,
Paisley, UK
Avidin /Biotin Blocking Kit Vector Laboratories Inc., Burlingham,
USA
Biozym LE Agarose Biozym Scientiﬁc GmbH, Hessisch
Oldenburg
Distilled water DNase/RNase Free Life Technologies Corp., Paisley, UK
Citric acid mono hydrate
C6H8O7 ·H2O
Merck KGaA, Darmstadt, Germany
Dulbecco’s Modiﬁed Eagle Medium Life Technologies, Darmstadt,
Germany
Eagle’s Minimum Essential Medium Life Technologies, Darmstadt,
Germany
Ethanol Carl Roth GmbH & Co. KG,
Karlsruhe, Germany
Ethidium bromide C12H20BrN9 amresco International GmbH,
Darmstadt, Germany
Ethylenediaminetetraacetic acid
disodium salt solution
Sigma-Aldrich, Co., St.Louis, USA
Fetal bovine serum Biochrom AG, Berlin, Germany
Formaldehyde Carl Roth GmbH & Co. KG,
Karlsruhe, Germany
Gelatine from cold water ﬁsh skin Sigma-Aldrich Co., St. Louis, USA
High Pure RNA Paraﬃn Kit Roche Diagnostics GmbH, Mannheim,
Germany
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Table 3.1: Chemicals and reagents
Substances Producer
Horse serum Vector Laboratories Inc., Burlingham,
USA
Hydrogen peroxide H2O2 Carl Roth GmbH & Co. KG,
Karlsruhe, Germany
Hydrochloric acid HCl Carl Roth GmbH & Co. KG,
Karlsruhe, Germany
ImmPACT DAB Vector Laboratories Inc., Burlingham,
USA
Isopropanol Carl Roth GmbH & Co. KG,
Karlsruhe, Germany
Meyer’s haematoxylin Carl Roth GmbH & Co. KG,
Karlsruhe, Germany
RevertAid H Minus First Strand cDNA
Synthesis Kit #K1631
Thermo Fisher Scientiﬁc Inc.,
Waltham, USA
peqGOLD Taq-DNA-Polymerase “all
inclusive”
Peqlab VWR International GmbH,
Erlangen, Germany
PrimerScript™ RT reagent Kit
(Perfect Real Time)
TAKARA Bio Inc., Otsu, Japan
Potassium chloride KCl Carl Roth GmbH & Co. KG,
Karlsruhe, Germany
Potassium dihydrogen phosphate
KH2PO4
Carl Roth GmbH & Co. KG,
Karlsruhe, Germany
RNeasy™ Mini Kit QIAGEN GmbH, Hilden, Germany
Sodium dodecyl sulfate (10%, pH 7.3) Sigma-Aldrich Co., St. Louis, USA
Sodium chloride NaCl Carl Roth GmbH & Co. KG,
Karlsruhe, Germany
Sodium hydroxide NaOH Carl Roth GmbH & Co. KG,
Karlsruhe, Germany
diSodiumhydrogen phosphate
dihydrate Na2HPO4
Merck KGaA, Darmstadt, Germany
Triton X100 Carl Roth GmbH & Co. KG,
Karlsruhe, Germany
Trizma® hydrochloride solution (1M,
pH 8.0) Tris–HCl
Sigma-Aldrich Co., St.Louis, USA
Vectastain ABC Kit Vector Laboratories Inc., Burlingham,
USA
Xylene Carl Roth GmbH & Co. KG,
Karlsruhe, Germany
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Table 3.2: Technical Devices
Device Model Manufacturer
Centrifuges 5415D Eppendorf AG, Hamburg,
Germany
4K15 Sigma, Deisenhofen, Germany
Gel imaging sytem Eagle Eye™ II Stratagene, Heidelberg,
Germany
Magnetic stirrer RCT basic IKA®-Werke GmbH & Co.
KG, Staufen, Germany
Microtome HM355 Thermo Fisher Scientiﬁc Inc.,
Waltham, USA
pH meter EL-30 Mettler-Toledo GmbH,
Giessen, Germany
Power supply Power PAC 300 Bio-Rad Laboratories, Inc.,
Hercules, USA
Shaker Mini shaker MS1 IKA®-Werke GmbH & Co.
KG, Staufen, Germany
Slide scanner Aperio CS2 Leica Biosystems Nussloch
GmbH, Nussloch, Germany
Spectrophotometers NanoDrop 2000c Thermo Fisher Scientiﬁc Inc.,
Waltham, USA
Steamer TEFAL Steam cuisine Groupe SEB Deutschland
GmbH, Frankfurt am Main,
Germany
Stereotaxis Lab standard stereotaxic
instrument
Stoelting Europe, Dublin,
Ireland
Thermal cycler GeneAmp™ PCR Sytem
9700
Applied Biosystems, Waltham,
USA
Thermomixer Thermomixer comfort Eppendorf AG, Hamburg,
Germany
Water bath TFB 35.000 Medite Medizintechnik,
Burgdorf, Germany
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3.2 Methods
All experiments were done at Institut für Allgemeine Pathologie und Pathologische
Anatomie der Technische Universität München (TUM), with the help of Sandra Baur
and Christine Grubmüller.
3.2.1 Collection of GBM patients data
The specimens for this retrospective study were collected at the Klinikum rechts der
Isar, TUM with patients’ consent according to the TUM medical faculty’s guidelines
for tissue preservation. All patients had signed informed consent dorms according
to the local ethics committee. Tissue samples for histopathological diagnosis and
molecular genetic analysis were acquired during tumour resection at the NeuroKopf-
Zentrum, Klinikum rechts der Isar, TUM. Tumour diagnoses of glioblastoma multi-
forme, WHO IV (Louis et al., 2007), were established by standard light-microscopic
evaluation of H&E sections, immunohistochemistry for IDH1 (R123H point mutation
(Nobusawa et al., 2009)), glial ﬁbrillary acidic protein (GFAP), Ki67, microtubule-
associated protein 2, tumour suppressor protein p53, epidermal growth factor re-
ceptor, and MGMT promoter methylation, and veriﬁed by two independent neu-
ropathologists (Prof. Dr. Jürgen Schlegel, Claire Delbridge) at Institute für Allge-
meine Pathologie und Pathologische Anatomie der TUM. Data of 135 GBM patients
were collected in this retrospective patient cohort study with a follow up of 3 years.
For analysis, only PGBM patients receiving neurosurgery, chemotherapy and radio-
therapy as described by Stupp et al. (2005) were included. 71 Patients were excluded
from analysis because of: diﬀerent therapy (only neurosurgery, only chemo- or only
radiotherapy), incomplete data, bad tissue quality, IDH1 mutation. Neurosurgery
on recurrent tumours is controversial (Sughrue et al., 2015) and therefore we are
pleased to present data on 28 secondary tumours of PGBM patients. IHC analysis
was performed blinded on FFPE tissue of primary and recurrent surgical specimens
of patients diagnoses as PGBM, WHO IV (Louis et al., 2007).
Table 3.3: Patient characteristics
female n = 26 male n = 39
min mean max min mean max
Age (in years) 40 60 78 20 59 80
overall survival (in days) 37 463 1437 22 607 2904
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3.2.2 Canine GBM samples
As described in Stoica et al. (2009), the incidence of canine GBM is unclear. There is
no routine therapy like tumour resection, chemo- and radiotherapy available like in
humans. Necropsies of the dog brain are not usually performed in detail. Biopsies
from one female, 12 years old Cocker Spaniel and one German Shepherd dog with
unknown age and sex diagnosed in 2014 in the neuropathological laboratory of the
Tierpathologie der Ludwig-Maximilians Universität as canine GBM, are analysed.
Both tumour samples show a tumour of the glia with necrosis, mitosis, atypic nuclei,
and neovascularisation comparable with the human GBM WHO IV.
IHC as described in Section 3.2.3 was performed on both biopsies. As positive
control for IHC served a liver of a 6 months old autopsied pug with hydrocephalus.
3.2.3 Immunohistochemistry analysis
Immunohistochemical method
Tissue sections of 2μm thickness are deparaﬃnised. All incubation steps are per-
formed in a humidiﬁed chamber. Epitope unmasking is performed with citric acid
based buﬀer (pH 6.0) or with EDTA (pH 8.0) for 30min in a steamer. The endoge-
nous peroxidase is quenched with 3% H2O2 for 20min at room temperature. To
minimize non-speciﬁc staining resulting from endogenous avidin-biotin activity it
is blocked with Avidin /Biotin blocking kit for 30min. Non-speciﬁc binding sites
are blocked with the blocking buﬀer described in Table 3.4. Each tissue section is
incubated in a humidiﬁed chamber with the in Table 3.5 described dilution of the
Table 3.4: Buﬀers and solutions
Buﬀer Ingredients
Blocking buﬀer 1 x PBS
1% Bovine serum albumin
0.1% Triton X100
0.2% Gelatin from cold water ﬁsh skin
2.5% Normal Horse Serum
PBS 10 x pH 7.4 140mM NaCl
2.7mM KCl
20mM Na2HPO4
1.8mM KH2PO4
Citrate buﬀer pH 6.0 2.1 g citric acid monohydrate
add up to 500ml H2O
10 x Tris buﬀer 60.5 g Tris
90 g NaCl
add up to 1000ml H2O
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Table 3.5: Antibodies used for IHC and IFC
Antibody Clone Company Dilution
ALDH1 44/ALDH BD, Heidelberg,
Germany
1:50
ALDH1A1 EP1933Y Novus Biologicals
Europe,
Cambridge, UK
1:1000
ALDH1A3 PA5-29188 Thermo Fisher
Scientiﬁc Inc.,
Waltham, USA
1:1000
Alexa ﬂour® 488 donkey-anti mouse Life technologies
Carlsbad, USA
1:500
Alexa ﬂour® 568 donkey-anti rabbit Life technologies
Carlsbad, USA
1:500
Anti-human Ki67 mib1 Dako Deutschland
GmbH, Hamburg,
Germany
1:50
biotinylated horse Anti-mouse IgG Vector
Laboratories Inc.,
Burlingham, USA
1:200
biotinylated horse Anti-Rabbit IgG Vector
Laboratories Inc.,
Burlingham, USA
1:200
biotinylated goat Anti-Rabbit IgG Kirkegaard &
Perry
Laboratories Inc.,
Maryland USA
1:1
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AB in blocking buﬀer overnight at 4℃. Followed by the incubation with the cor-
responding biotinylated secondary AB for 30min at room temperature. Afterwards
the ABC-Kit is applied for 30min. Finally, tissues slides are incubated with Imm-
PACT DAB chromogen working solution for 4 to 8min and counter stained with
Meyer’s haematoxlin. Liver tissue serves as positive control for all ALDH isoforms.
Negative controls for all ALDH isoforms were obtained by substituting primary AB
with blocking buﬀer.
All routine stainings and IHC of ALDH1 are performed during routine diagnosis
and were done with an automated staining system.
Immunoﬂuorescence method
For the immunoﬂuorescence staining specimens are deparaﬃnized. The epitope
unmasking with EDTA (pH 8.0) for 30min is performed in a steamer. Followed
by blocking with Blocking buﬀer for 30min at room temperature. After washing
twice in 1 x PBS the in Blocking buﬀer prediluted AB is applied (Table 3.5) to the
sample and incubated overnight at 4℃. The next day the slide is wahsed twice with
1 x PBS and then incubated with the prediluted secondary ﬂuorescence labeled AB
(Table 3.5) for 45min at room temperature. Before adding prediluted Hoechst dye
to the tissue sections, it is washed twice with 1 x PBS.
Immunohistochemistry Score
The IHC reaction was rated in cooperation with Claire Delbridge. The percentage
of tumour cell with stained cytoplasm was scored, intensity of the staining was
taken into account. We deﬁned two categories of IHC reaction: none and up to
10% positive cells count as no IHC reactivity, more than 10% positive cells as IHC
reactivity.
3.2.4 Analysis of ALDH isoforms on the mRNA level
Isolation of mRNA
FFPE Material Expression of diﬀerent ALDH isoforms on mRNA level is analyzed
with reverse transcription PCR (RT-PCR) with Taq Polymerase. The specimens are
the same as for the IHC. For extraction of the RNA of formalin-ﬁxed paraﬃn-
embedded tissue the High Pure RNA Paraﬃn Kit from Roche Diagnsotics GmbH is
used. The guidelines of the producer are followed. The paraﬃn embedded tissue is
cut into 10μm thick sections. After drying the tissue and following deparaﬁnisation,
sections are microdissected from the slide with a new sterile single-use scalpel and
placed in an RNAse free reaction tube. 100μm Tissue Lysis Buﬀer, 16μl 10% SDS
and 40μl Proteinase K working solution is poured to each sample and incubated
overnight with brief vertex in several intervals at 55℃. The next day, 325μl Bind-
ing Buﬀer and 325μl ethanol absolute is added. Than the lysate is transferred into
a combined High Pure Tube and a collection tube. After centrifugation for 30 sec at
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Table 3.6: Oligonucleotide sequences for RT-PCR
Gene Accession
number
(NM_)
Sequences (5’–3’)
f: forward, r: reverse Tm(℃)
Product
size (bp)
ALDH1A1 000689 f TGTTAGCTGATGCCGACTTG 58.27 71
r CTGGCCCTGGTGGTAGAATA 58.49
ALDH1A2 001206897 f AGTGGGAGAGTGTTCCCTGT 60.10 79
r TATCTGCCTTGTCTGCTTCTTGA 59.74
ALDH1A3 000693 f TCGACCTGGAGGGCTGTATTA 60.06 89
r GTTGTCATCTGTGGGGATGGT 60.00
ALDH2 000690.3 f GGAAAACATTCCCCACCGTC 59.11 85
r GCCTTGTCCACATCTTCCTTGT 60.82
ALDH3A1 001135168.1 f TACATAGCCCCCACCATCCT 59.73 71
r GGCCCGAAGATCTCCTCTTG 59.89
ALDH7A1 001201377.1 f ACTGCGAGGCGACTGTTTAT 59.75 89
r TTCCCAACTCGGATCTGTGC 60.04
ALDH8A1 022568.3 f GCACATTTGGAGAAAGTCAGAAGT 59.72 83
r TTATCCACTCCCTCACCGCA 60.62
GFAP 002055 f GCAGATTCGAGAAACCAGCC 59.27 76
r GGTCTTCACCACGATGTTCCT 60.00
GAPDH 002046.5 f CTCTGCTCCTCCTGTTCGAC 59.83 75
r ATGGTGTCTGAGCGATGTGG 60.11
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8000 g the ﬂow through is discarded. Repeated centrifugation drys the ﬁlter ﬂeece
completely. 500μl Wash Buﬀer 1 working solution is given to the upper reservoir,
followed by another centrifugation (15 sec at 8000 g) and the discharging of the ﬂow
through. 300μl of Wash Buﬀer 2 working solution is added. The sample is cen-
trifugated at 8000 g for 15 sec. After ward discard the ﬂow through. The High Pure
Filter Tube is centrifugated at 13000 g for 2min. Than the High Pure Filter Tube is
placed into a fresh 1.5ml reaction tube. 90μl of the Elution Buﬀer is poured in be-
fore centrifugation at 8000 g for 15 sec. After adding 10μl DNase Incubation Buﬀer
and 1μl DNase 1 working solution to the eluate and mixing it, samples are incubated
for 45min at 37℃. Followed by adding 20μl Tissue Lysis Buﬀer, 18μl 10% SDS and
40μl Proteinase K working solution and an incubation for 1 h at 55℃. The reaction
tube is replaced. Afterwards ﬁrst steps are repeated as following: 325μl Binding
Buﬀer and 325μl ethanol absolute is added to the sample. Than the lysate is trans-
ferred into a combined High Pure Tube and a collection tube. After centrifugation
for 30 sec at 8000 g the ﬂow through is discarded. The centrifugation is repeated
to dry the ﬁlter ﬂeece completely. 500μl Wash Buﬀer 1 working solution is given
to the upper reservoir followed by another centrifugation (15 sec at 8000 g) and the
discarding of the ﬂow through. 300μl of Wash Buﬀer 2 working solution is added.
The sample is centrifugation at 8000 g for 15 sec, and the ﬂow through is discarded.
The High Pure Filter Tube is again centrifugated at 13000 g for 2min. The High
Pure Filter Tube is placed into a fresh 1.5ml reaction tube. 90μl Elution Buﬀer is
given into the tube before centrifugation at 8000 g for 15 sec. The High Pure Filter
Tube is again placed into a fresh reaction tube. To the sample 50μl of the Elution
Buﬀer is added. After incubating for 1min at room temperature and centrifugation
for the last time for 1min at 8000 g the eluted RNA is collected. RNA is measured by
NanoDrop, and stored at −80℃ or directly transferred into cDNA by the RevertAid
H Minus First Strand cDNA Synthesis Kit from Thermo Fisher Scientiﬁc. Protocol
as following. The following reagents are mixed within a sterile, nuclease-free tube
on ice: Template RNA (0.01-0.1 ng), 1μl random hexamer primer and nuclease-free
water up to 12μl and than incubated for 5min at 65℃. The sample is placed on ice
after spin down. 4μl 5 x Reaction Buﬀer, 1μl RiboLock RNase Inhibitor (20U/μl),
1μl RevertAid H Minus M-MuLV Reverse Transcriptase (200U/μl) is given to the
sample, mixed and incubated ﬁrst for 5min at room temperature and than for 60min
at 42℃. The reaction is terminated by heating up to 70℃ for 5min. The cDNA is
stored at −20℃ for short term and for long term at −80℃.
Cell line LN18 The Glioblastoma cell line LN18 was used as a positive control for
all ALDH isoforms, GFAP, and GAPDH. LN18 cells were bought at ATCC™ and was
isolated from a 65 years old male patient with PGBM grade WHO IV (Diserens et al.,
1981).
The RNA isolation is done with the RNeasy™ Mini Kit. The cells are harvested,
when grown to 80% conﬂuency in medium. After washing the cells twice with cold
PBS, 600μl RLT Lysis Buﬀer and 10μl betaMercaptoethanol is given to the cells.
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The cells are collected with a sterile cell scraper, transferred into a reaction tube
and resuspended 5 x with a 20G needle. 600μl 70% Ethanol is added to the sample
and mixed gently. Sample is transferred into a High Pure Tube, and centrifugated
at 200 g for 15 sec before discarding the ﬂow through. Carefully 10μl DNase 1 and
70μl Buﬀer RDD is added and following incubation for 15min at room temperature.
350μl Buﬀer RW1 is added thereafter samples are centrifugated at 200 g for 15 sec.
After discarding ﬂow through reaction tube is replaced with a new one. 500μl
RPE Buﬀer is added again and centrifugated at 200 g for 2min, before discarding
the ﬂow through. Membrane is dried with another centrifugation at 1300 g 1min.
100μl DNase/RNase-Free Water is pipetted to the sample before centrifugation at
200 g for 1min at 4℃ to collect eluted RNA. The with the NanoDrop measured RNA
is stored at −80℃ or directly transferred into cDNA.
The reverse transcription is done following the instruction of PrimerScript™ RT
reagent Kit (Perfect Real Time) of TAKARA Bio Inc.. Brieﬂy: mixed 2μl 5 x
PrimeScript Buﬀer, 0.5μl PrimeScript RT Enzyme Mix 1, 0.5μl Oligo dT Primer
50μM, 0.5μl Random hexamers 100μM, and the isolated RNA (max 500 ng) and
ﬁlled up to 10μl with DNase/RNase free water is incubated for 15min at 37℃, than
5 sec at 85℃ and than cooled down to 4℃. cDNA is stored at −20℃.
Polymerase chain reaction
All Primers are designed with the help of Primer-Blast (Ye et al., 2012) and pur-
chased by Sigma-Aldrich. The annealing temperatures for RT-PCR for respective
primer pairs are described in Table 3.6. PCR Mastermix for RT-PCR was prepared
as described in Table 3.7. Program of RT-PCR is summarized in Table 3.8.
Quantiﬁcation of MGMT promoter methylation The quantiﬁcation of MGMT pro-
moter methylation was assessed by speciﬁc relative quantitative real time PCR
technique named MethyQESD, as described by Bettstetter et al. (2008) and per-
formed during routine diagnosis. In short, the endonucleases Hin61 (methylation-
Table 3.7: PCR Mastermix for RT-PCR
Substance Volume (μl)
H20 31.2
10 x buﬀer 5
Enhancer 10
dNTPS 1
Forward primer (10μM) 1
Reverse primer (10μM) 1
Taq Polymerase 0.5
cDNA (from 500 ng RNA) 0.3
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Table 3.8: RT-PCR Program
Temp. (℃) Duration
Denaturation 95 5min single
Denaturation 95 30 s ∣∣
∣
∣
∣
∣
35 cyclesPrimer annealing 59 or 56 30 s
Elongation 72 30 s
Elongation 72 7min single
Cooling 4 single
quantiﬁcation digestion) and XabI/DraI (methylation independent calibrator diges-
tion) were applied. After the digestion, MGMT promoter methylation status was
determined by relative quantitative real-time PCR using the LightCycler 480. For
positive control digested DNA of SW48 was used, for negative control non-methylated
blood DNA. The proportion of methylated template was calculated from the diﬀer-
ence of the cycle threshold values from the two endonucleases. MGMT negative are
patients with less than 8% MGMT promoter methylation and MGMT positive are
patients with more than 8% MGMT promoter methylation (Quillien et al., 2012).
Gel electrophoresis Following PCR, mix 5μl products with 1μl DNA loading dye
and separate on 2.5% Agarose gel. A 25 bp DNA ladder is used to distinguish
between speciﬁc and unspeciﬁc bands. Human universal gene and LN18 served as
positive control. Normal brain and liver were evaluated as well.
3.2.5 Mouse experiments
The U87-MG impalantation into the NMRI-nude mouse (HsdCpb:NMRI-Foxn1nu, n =
14) were done by Dr. Velia Hülsmeyer and implantation of Gl261 cells into C57BL/6JRj
mice (n = 10) were done by myself. Both experiments were done at the Institut für
Allgemeine Pathologie und Pathologische Anatomie der TUM and were approved by
the Veterinäramt München and in accordance to the German welfare law (Az. 55.2-
1-54-2532-6-11 and Az. 55.2.1-45-2532.0-83-14). Mice were housed under speciﬁc
pathogen-free conditions.
Table 3.9: summary of mouse experiments
C57BL/6JRj NMRI-nude
control 10 7
treated with DSF 0 7
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Orthotopic implantation
The orthotopic implantation into the brain was done following the descriptions
for stereotactical implantation of Yamada et al. (2004). In short, the mouse is
anaesthetised with a combination of fentanyl (0.05mg/kg bodyweight), meditomidin
(0.5mg/kg bodyweight), and midazolam (5mg/kg bodyweight). The mouse is pre-
pared for the surgical intervention including shearing, cleaning of the operation area,
and ﬁxation into the stereotaxic instrument (Figure 3.1). Before opening the skin,
local anaesthesia with bubivacain is applied. For correct implantation the coordi-
nates of bregma and lambda are recorded. The height of bregma and lambda were
adjusted to the same level to ensure correct perpendicular injection of tumour cells.
The injection site was calculated from bregma. 2mm lateral and 0.5mm anterior of
bregma a 0.47mm wide hole is drilled. A Hamilton syringe (26GS) containing the
tumour cells is ﬁxed to the stereotactical frame and guardedly inserted over 5min
to a depth of 3mm. Over 7min tumour cells are injected and after waiting another
2min the syringe is carefully removed over 7min. After sewing with a absorbable
thread, mouse is taken out of stereotactic frame. Atipamezol (2.5mg/kg body-
weight), ﬂumazenil (0.5mg/kg bodyweight), and naloxon (1.2mg/kg bodyweight)
are injected to antagonize the anaesthesia. The recovery period is short because of
quick inhibition of fentanyl, meditomidin, and midazolam.
(a) Stereotaxic instrument (b) Mouse ﬁxed in stereotaxic instrument
Figure 3.1: a) Used stereotaxic instrument for mouse operation to assure correct
implantation into the striatum. b) Mouse ﬁxed and with opened cutis. Sutures of
cranium are visible: sutura coronalis, sutura sagitalis, sutura occipitalis.
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Termination criteria and plan of action
Mice were controlled regularly, in the ﬁrst week after implantation every 6 to 8 hours,
following weeks every day and if mouse condition impaired more frequently. An
examination of ﬁtness and general performance was done according to the Table 3.10
and if needed action was followed described in Table 3.11.
Table 3.10: Termination criteria for intracranial implantation
degree of
strain
0 I II III
points per
symptom
complex
0 1 2 3
central
nervous
system
symptoms
none ataxie,
starting head
tilt
ataxie, head
tilt
paralysis,
seizures, not
eating
behaviour active, curios hyperactive
or hypoactive,
reduced
conciseness
hyperkinesia,
reduced
conciseness
even after
stimulus,
reluctant to
move
isolation,
paresis,
plegia, torti
collis,
seizures, au-
toaggressive,
vocalisation,
tremor
appearance shiny and ﬂat
coat, clean
eyes
dull eyes, no
grooming, too
much
grooming
truncated
coat, no
grooming
dirty,
truncated
coat, rapid
breathing,
skin tone
reduced
weight change
in %
0-5 6-10 11-19 >19
pain
symptoms
none starting head
tilt,
nystagmus
abnormal
body posture,
bent back,
normal after
stimulus
vocalisation,
agression, au-
tomutilation,
bent back
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Table 3.11: Action: for intracranial implantation
degree of strain additive
symptom points
intensity of strain action
0 0 none none
I 1-3 light daily check, if
aggravate sacriﬁce
II 4-6 moderate daily check, therapeutic
intervention if possible
without inﬂuence of
experiment
III >7 high immediate termination,
sacriﬁce
After 8 weeks NMRI-nude mice and after 2 weeks C57BL/6JRj mice were sacriﬁced
with a lethal doses of pentobarbital-natrium (600mg/kg bodyweight) after narcosis
with fentanyl (0.05mg/kg bodyweight), meditomidin (0.5mg/kg bodyweight), and
midazolam (5mg/kg bodyweight).
Experimental inhibition of ALDH
Disulﬁram (DSF) is a known ALDH inhibitor (Eneanya et al., 1981), eﬀecting the
tumour growth (Loo and Clarke, 2000; Wang et al., 2013; Yakisich et al., 2001). In
clinical trails it is used for PGBM therapy (Kast et al., 2014), without any success. To
evaluate the eﬀect of DSF treatment on GBM in vivo, 7 NMRI-nude mice were treated
intraperitoneal 7 days after tumour implantation with 100mg/kg bodyweight DSF
per day.
Magnetic resonance imaging of mice
To ensure tumour growth mice are checked with MRI 7 Tesla. While scanning mice
are anaesthetized with isoﬂurane, a general inhalation anaesthetic, enabling a rapid
onset and a rapid recovery without any analgesic eﬀect. Mouse is placed into a
chamber which is ﬂoated with isoﬂurane. Withdrawl reﬂex is checked to assure
depth of anaesthesia. Mouse is placed onto a heated bed within the MRI for 30min
to perform scan (Figure 3.2).
Perfusion of mouse
Cardialgic perfusion is performed to accelerate ﬁxation of organs before autolysis
can begin. Another advantage of perfused organs is that they are less likely develop
artefact and are not sensitive to handling. The performed perfusion uses the vascular
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Figure 3.2: MRI pictures of a C75BL/6JRj mice with Gl261 tumour at the right hemi-
sphere. Coronal sections of T1 weighted images. Tumour marked with cross.
system of the sacriﬁced animal (Figure 3.3). The sacriﬁced animal is ﬁxed on its
back with each limb ﬁxed to Styrofoam. To open the abdomen an incision of the
midline skin is made from the pelvis to the thoracic inlet. Abdomen is carefully
opened so intestines are not opened. The xyphoid process is gasped with forceps
and the diaphragma is opened to allow lung to collapse. A collapsed lung reduces
risk of incise it during the opening of the thorax. A butterﬂy is placed into the
left ventricle and ﬁxed to the Styrofoam. 1 x PBS perfusion is started. The right
auricle of the heart is opened when liquid accumulated. Blanching of the liver and
the spleen are taken as sign for good perfusion. When liquid is dripping out of nose,
perfusion pressure is to high.
Preparation of the brain
After pefusion the scull is opened beginning at the foramen magnum. With forceps
and a dull scissors the os occipitale and the os frontale are removed. When the
dorsal brain is completely visible the nervi optici and the bulbi olfactori are cut
with a spatula. The brain is ﬁxed overnight in 4% formalin on shaker for immersion
ﬁxation. The next day, ﬁxation is checked and tissue is placed into the dewatering
machine to be embedded afterwards in paraﬃn.
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Figure 3.3: Schema of perfusion. A butterﬂy is placed into the left ventricle of
the heart. With 1 x PBS the all vessels of the body circulation and the pulmonary
circulation are ﬂushed. Blanching of the liver and the spleen are taken as reference
for perfusion status.
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3.2.6 Culture of cell line LN18, U87-MG, Gl261, C6, and F98
All cells are cultured at 37℃ at 5% CO2. Growing medium for LN18 and U87-
MG is the Eagle’s Minimum Essential Medium with 10% fetal bovine serum, for
Gl261, C6, and F98 the Dulbecco’s Modiﬁed Eagle Medium with 10% fetal bovine
serum. Medium renewal is done twice or three times a week. When cells are grown
conﬂuent, a subcultivation ratio between 1:3 and 1:5 is chosen. Mycoplasma test
are done regularly on a quarterly period basis.
3.2.7 Cell pellet
The cells are harvested with trypsin and than ﬁxed in 4% formalin for 15min. After
centrifugation at 1800 g for 10min at room temperature, the supernatant is decanted,
and cells are resuspended in 5ml 70% ethanol for 30min and than 100% ethanol.
The ﬁxed cells are resuspended in 1% agarose and chilled on ice. Afterwards sample
is prepared like routine FFPE material.
3.3 Summary of samples
Table 3.12: Summary of samples and methods
method speciﬁcation type species number of samples
IHC PGBM tissue human 65
SGBM tissue human 28
tissue canine 2
tissue mouse 24
cellpellet human 1
cellpellet mouse 1
cellpellet rat 2
IFC PGBM tissue human 65
PCR PGBM tissue human 28
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4.1 Human PGBM cohort analysis
The aim of this study was to investigate the immunoreactivity of the ALDH isoforms
and their power as prognostic factor for the survival of PGBM patients. In this
retrospective study, patients with following properties were included:
1. primary glioblastoma multiforme WHO IV (Louis et al., 2007)
2. resection between 2003 and 2013
3. IDH1 wild type
4. treatment
• surgical resection of primary tumour
• radiotherapy
• chemotherapy with TMZ
• resection of secondary tumour (28 patients)
5. good follow-up.
Primary tumour tissue samples were obtained by surgical resection before radi-
ation and chemotherapy, secondary afterwards. The patient cohort consists after
exclusion of 65 patients (exclusion criteria in Section 3.2.1). We enrolled 26 female
and 39 male patients with a mean age at diagnosis of 60 years and 59 years, respec-
tively. The MOS were 15.4 months for female and 20.2 months for male patients,
respectively. 11 patients lived another 2.5 years after diagnosis and count therefore
as long-time survivors deﬁned by Smoll et al. (2013). Further characteristics are
summarised in Table 3.3 (p. 16) and an overview of patients data can be found in
Table 9.1 (p. 68).
4.1.1 Immunohistochemistry
IHC staining was performed as described in Section 3. We deﬁned two categories of
IHC reaction: none or up to 10% positive cells count as no IHC reactivity, more than
10% positive cells as IHC reactivity. Scoring was done blinded without knowledge
of patients data.
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Figure 4.1: Survival distribution of female (n = 26) and male (n = 39) PGBM
patients. Three male and one female patient diﬀer in survival more than 1.5 times
to the interquartile range and are shown as cycles.
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(a) IHC ALDH1 liver
(b) IHC ALDH1 positive (c) IHC ALDH1 negative
Figure 4.2: IHC, 400 x, ALDH1. FFPE sections of human liver served as positive
control for all ALDH isoforms. Positive primary PGBM with >10% expression of
patient No. 95, negative primary PGBM with <10% reactivity of patient No. 9
respectively.
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(a) IHC ALDH1A1 liver
(b) IHC ALDH1A1 positive (c) IHC ALDH1A1 negative
Figure 4.3: IHC, 400 x, ALDH1A1. FFPE sections of human liver served as positive
control for all ALDH isoforms. Positive primary PGBM with >10% expression of
patient No. 95, negative primary PGBM with <10% reactivity of patient No. 9
respectively.
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(a) IHC ALDH1A3 liver
(b) IHC ALDH1A3 positive (c) IHC ALDH1A3 negative
Figure 4.4: IHC, 400 x, ALDH1A3. FFPE sections of human liver served as positive
control for all ALDH isoforms. Positive primary PGBM with >10% expression of
patient No. 95, negative primary PGBM with <10% reactivity of patient No. 9
respectively.
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Immunohistochemistry of primary PGBM
In the IHC staining of the PGBM tumours for ALDH1, ALDH1A1 and ALDH1A3, at
least two diﬀerent cells types can be identiﬁed (Figure 4.5). ALDH1A1 positive cells
are multipolar and star-like. Their end-feet tend to terminate on blood vessel walls,
and they can mostly be found in the tumour surrounding tissue. The epithelium of
the blood vessel itself reacts positive, as well as macrophages. In contrast, ALDH1A3
positive cells are widely distributed in the tumour area. They are multipolar and
star-like, like the ALDH1A1 positive cells. ALDH1 staining does stain both cell types.
The IHC staining pattern of ALDH1 was unevenly disseminated among the tumour
tissue. In detail: 55 (84.6%) patients had an ALDH1 expression, 10 (15.4%) did
not. In general the ALDH1A1 expression was low. Most (n = 43, 66.2%) of the
patients were ALDH1A1 negative, only 22 (33.8%) patients had protein expression
of ALDH1A1. For ALDH1A3, 16 (24.6%) patients showed no immunoreactivity in
contrast to 49 (75.4%) showing expression.
The MOS of PGBM for the ALDH isoforms is shown in Figures 4.6, 9.1, 9.2. Only the
ALDH1 expression can conﬁdently be correlated with the MOS. The adjusted hazard
ratio for mortality associated with being ALDH1 positive (n = 55, MOS = 366 days)
was 3.06 (p = 0.0042). Patients without ALDH1 (n = 10) had a MOS of 922 days. The
diﬀerences in MOS between ALDH1A1 positive patients (n = 22, MOS = 382 days) and
ALDH1A1 negative patients (n = 43, MOS = 446 days), and ALDH1A3 positive patients
(n = 49, MOS = 373 days) and ALDH1A3 negative patients (n = 16, MOS = 495 days)
do not show signiﬁcance with a odds ratio of 1.23 (p = 0.43) and 1.17 (p = 0.59),
respectively (Figure 9.2).
ALDH1A1 and ALDH1A3, are not predictive for the MOS of PGBM patients by them-
selves, but might be in combination (Figure 4.7). Double positive (ALDH1A1 and
(a) ALDH1A1 (b) ALDH1A3
Figure 4.5: IHC, 400 x, ALDH1A1 and ALDH1A3. Staining of primary PGBM of patient
No. 106. Diﬀerent cell types are reacting with the ALDH isotype antibody. ALDH1A1
positive cells have end feet, ending on vessels. ALDH1A3 cells have often two nuclei.
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Figure 4.6: Survival of patients with diﬀerent ALDH1 expression in primary PGBM.
ALDH1 positive (n = 55) patients have a MOS of 366 days, ALDH1 negative (n = 10)
patients have a MOS of 922 days.
ALDH1A3) patients (n=6) have a MOS of 516 days in contrast to totally negative
patients (n=5) with a MOS of 870 days. The multiple Cox regression analysis while
adjusting for age showed that double positive PGBM patients have a risk of disease
progression with a hazard ratio 3.5 (p = 0.091).
We could not predict the RFS of 28 patients with secondary PGBM with one of the
scorings of ALDH isoforms or in combination of the primary PGBM (Figure 9.3, 9.4,
9.5).
Evaluation of longtime survivors Long time survivors are from special interest
because of their obvious diﬀerent tumour reaction to therapy. 11 longtime survivors
were analysed in terms of ALDH expression. Every category of expression is present
but no diﬀerence in MOS is striking.
Table 4.1: Immunoreactivity of primary PGBM of longtime survivors
ALDH1 ALDH1A1 ALDH1A3
positive 5 2 8
negative 6 9 3
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Figure 4.7: Survival of primary PGBM patients with diﬀerent combinations of
ALDH1A1 and ALDH1A3: double negative patients (n = 15) have a MOS of 517 days,
double positive patients (n = 19) have a MOS of 357 days, ALDH1A1 positive and
ALDH1A3 negative patients (n = 3) have a MOS of 473 days, ALDH1A1 negative and
ALDH1A3 positive patients (n = 28) have a MOS of 410 days.
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Gender separated analysis Another aspect of this study was, to have a look into
gender diﬀerences. In general, women in this cohort analysis have a shorter overall
survival than men. The Cox regression analysis while adjusting for age showed that
ALDH1 positive female PGBM patients have a risk of disease progression with a
hazard ratio 4.7 (p = 0.021), male PGBM patients a hazard ratio 3.5 (p = 0.023)
(Figure 4.8).
However, isotype speciﬁc analysis of ALDH reveals striking diﬀerences. The Cox
regression for the hazard function of ALDH1A1 expression revealed that female PGBM
patients with a ALDH1A1 expression (n = 7, MOS = 329 days) have a 2.81 (p = 0.048)
higher risk for disease progression than female patients without ALDH1A1 expression
(n = 19, MOS = 448 days, adjusted for age, Figure 4.9). The mutiple Cox regression
analysis after adjusting to the age showed that double positive for ALDH1A1 and
ALDH1A3 female PGBM patients have a risk of disease progression with a hazard
ratio 3.6 (p = 0.018).
MOS of male PGBM patients is not aﬀected by the ALDH1A1 expression, but
ALDH1A3 is important. ALDH1A3 expressing (n = 28, MOS = 370 days) was in
males associated with a shorter live (ALDH1A3 negative n = 11, MOS = 623 days,
Figure 9.9), albeit insigniﬁcant (Odds ratio 1.30, p = 0.46).
Immunohistochemistry of secondary PGBM
The IHC stainings of the recurrent PGBM tumours for ALDH1, ALDH1A1, and ALDH1A3
were intended as a test if the intensity, the amount of cells, or the reacting cell
fraction itself changes in comparison to the primary tumour, but no diﬀerence was
seen. Even the distribution between negatively and positively reacting patients did
not change compared to the primary tumour stainings. 22 (78.6%) samples had an
ALDH1 expression, 6 (21.4%) did not. ALDH1A1 expression was seen in 10 (35.7%)
patients. For ALDH1A3, 23 (82.1%) patients showed IHC reactivity.
The IHC score of each protein and each patient in the primary and recurrent
tumours changes usually not, but in some cases to a higher and less often to a lower
score (Table 4.2). No trend can be derived.
The staining of the relapse tumours regarding the IHC expression of ALDH did not
show any correlation to the MOS (Figures 9.6, 9.7, 9.8).
Table 4.2: IHC reactivity changes from primary to secondary PGBM.
Protein less reactivity same reactivity higher reactivity
ALDH1 4 19 5
ALDH1A1 3 21 4
ALDH1A3 2 21 5
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Figure 4.8: Survival of PGBM patients separated by sex and ALDH1 expression. fe-
male: ALDH1 positive (n = 22) have a MOS of 368 days ALDH1 negative (n = 4) have
a MOS of 844 days. male: ALDH1 positive (n = 33) have a MOS of 366 days ALDH1
negative (n = 6) have a MOS of 922 days.
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Figure 4.9: Survival of PGBM patients separated by sex and ALDH1A1 expression.
female: ALDH1A1 positive (n = 7) have a MOS of 329 days ALDH1A1 negative (n = 19)
have a MOS of 448 days. male: ALDH1A1 positive (n = 15) have a MOS of 473 days
ALDH1A1 negative (n = 24) have a MOS of 410 days.
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Figure 4.10: Survival of female primary PGBM patients. Double positive patients
for ALDH1A1 and ALDH1A3 (n = 6) have a MOS of 211 days, all other combinations
(n = 20) have a MOS of 423 days.
4.1.2 Double immunoﬂorescence for ALDH1A1 and ALDH1A3 with Ki67
To further investigate the mitotic activity of ALDH1A1 and ALDH1A3 positive cells, we
performed a double staining. The double IFC was performed on the same tissues of
the PGBM patients cohort as the IHC stainings. The combinations ALDH1A1 and Ki67,
and ALDH1A3 and Ki67 were performed (Section 3). We saw more double reactive
cells for ALDH1A3 and Ki67 than for ALDH1A1 and Ki67, as shown in Figure 4.11 and
Figure 4.12.
4.1.3 MGMT methylation status and expression of diﬀerent ALDH1
isoforms
As mentioned in Section 1.1, the stable prognostic marker for PGBM is the MGMT
promoter methylation status. Patients with methylated MGMT promoter respond
better to standard therapy (Stupp et al., 2009). The MGMT promoter methylation
of the patients was determined during diagnosis. Cut oﬀ for MGMT promoter methy-
lation was set to below 8% for non methylated and above of 8% for methylated,
accordingly to Quillien et al. (2012).
To investigate if one of the ALDH1 isoforms is another reliable marker for MOS
of GBM patients as described by Schäfer et al. (2012), we analysed IHC expression
of ALDH1, ALDH1A1, and ALDH1A3 together with the MGMT status. The general
opinion of the favorable outcome of MGMT promoter methylated patients can be
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(a) DAPI (b) Ki67
(c) ALDH1A1 (d) DAPI, Ki67, ALDH1A1
Figure 4.11: IFC, 400 x, DAPI, Ki67, ALDH1A1. Secondary PGBM sample of patient
No. 50. ALDH1A1 positive cells are not positive for Ki67.
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(a) DAPI (b) Ki67
(c) ALDH1A3 (d) DAPI, Ki67, ALDH1A3
Figure 4.12: IFC, 400 x, abbreviationstylecommandDAPI, Ki67, ALDH1A3. Secondary
PGBM sample of patient No. 50. Double positive cell for ALDH1A3 and Ki67.
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supported by our data (Figure 4.13) (Stupp et al., 2009).
The combined analysis (Figures 4.14, 9.10 9.11) of the expression of ALDH iso-
forms and MGMT promoter methylation status show that the combination of MGMT
promoter methylated and ALDH1 IHC negative status elongates MOS (Figure 4.14)
which is in consent with the data from Schäfer et al. (2012). The Risk of pa-
tients to die with MGMT promoter methylation and being ALDH1 positive (n = 19,
MOS = 463 days) is 2.68 times (p = 0.047) higher than ALDH1 negative patients
(n = 5, MOS = 870 days).
The observations of the survival of PGBM patients with MGMT promoter methy-
lation, ALDH1A1 positive (n = 9, MOS = 373 days) show that they live shorter than
ALDH1A1 negative patients (n = 15, MOS = 664 days), although the number of obser-
vation is not suﬃcient to gain statistical signiﬁcance (odds ratio 1.85, p = 0.188). For
ALDH1A1 expression in combination without MGMT promoter methylation, there is
no diﬀerence (positive n = 28,MOS = 391 days, negative n = 13,MOS = 350 days,
Figure 9.10b).
There is also no diﬀerence in MOS of patients with diﬀerent ALDH1A3 expression
and MGMT promoter methylation status: patients without MGMT promoter methy-
lation and with ALDH1A3 (n = 28) have a MOS of 344 days and patients without
ALDH1A3 (n = 13) MOS of 473 days; patients with MGMT promoter methylation and
with ALDH1A3 (n = 21, MOS = 498 days) do not live shorter than patients without
ALDH1A3 (n = 3, MOS = 664 days), due to small number of patients, no signiﬁcance
was analysed.
4.1.4 ALDH expression by RT-PCR
RT-PCR was performed out of the same patient tissue as the IHC, as described in
Section 3.2.4, with primers listed in Table 3.6. As a positive control for all ALDH
proteins LN18 and human universal gene were used (Table 4.4). Liver and normal
brain tissue were analyzed as reference. We isolated RNA out of 36 FFPE primary
PGBM tumour samples. We could not isolate a suﬃcient amount of material out
of two samples due to the small size of available tumour tissue. GFAP and GAPDH
were used as house keeping genes to evaluate cDNA content. Negative samples were
excluded from further analysis (Figure 4.15).
Table 4.3: MGMT and ALDH1
ALDH1
positive negative
MGMT promotor methylated 19 5
MGMT promoter not methylated 36 5
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Figure 4.13: Survival of patients MGMT promoter methylated (n = 24, MOS =
524 days) and MGMT promoter not methylated (n = 41, MOS = 357 days) in primary
PGBM. The risk of death of MGMT promoter methylated PGBM patients is 0.57 times
(p = 0.048) smaller than counterpart.
Table 4.4: RT-PCR of controls
ALDH
Specimen GFAP GAPDH 1A1 1A2 1A3 2 3A1 7A1 8A1
LN18 + + + + + + + + +
Liver − − − − − − − − −
human ref. gen + + + + + + + + +
brain + + − − − − − − −
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Figure 4.14: Survival of patients with or without MGMT promoter methylation in
combination with ALDH1 expression in primary PGBM. No MGMT promoter methy-
lation ALDH1 positive patients (n = 36) have a MOS of 344 days compared to ALDH1
negative patients (n = 5) with a MOS of 870 days. With MGMT promoter methyla-
tion ALDH1 positive patients (n = 19) have a MOS of 463 days compared to ALDH1
negative patients (n = 5) with a MOS of 1437 days.
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Figure 4.15: RT-PCR of primary PGBM with GFAP of all patients with secondary
PGBM. Patients with non speciﬁc binding of primers were excluded from analysis
due to insuﬃcient extraction or degenerated mRNA.
Except 6 (25%) patients all are ALDH1A1 positive, which is in contrast to the IHC
expression of ALDH1A1. 66.2% of patients did show no or less than 10% immunore-
activity to ALDH1A1. ALDH1A2 was detectable in 7 cases. 17 (60%) patients are
positive for ALDH1A3, which is in accordance to the IHC staining. 3 out of 24 sam-
ples were ALDH2 positive, 9 (37%) for ALDH7A1. In the collective only one sample
was positive for ALDH3A1, one sample for ALDH8A1. No pattern of combinations of
diﬀerent ALDH isoforms can be detected (Table 9.4).
(a) ALDH1A1 (b) ALDH1A2 (c) ALDH1A3 (d) ALDH2
(e) ALDH3A1 (f) ALDH7A1 (g) ALDH8A1
Figure 4.16: RT-PCR of ALDH isoforms (25 bp marker, Patient No. 2, 25, and 47,
as positive control LN18 and the non template control). ALDH1A1: Patient No. 2,
25, 47, LN18 positive. ALDH1A2: Patient No. 2, 25, LN18 positive, patient No. 47
negative. ALDH1A3: patient No. 2, 25, No. 47, LN18 positive. ALDH2: No. 25, LN18
positive, patient No. 2, 47 negative. ALDH3A1: LN18 positive, patient No. 2, 25, 47
negative. ALDH7A1: patient No. 25 and LN18 positive, patient No. 2, 47 negative.
ALDH8A1: patient No. 2, 25, 47 and LN18 negative.
4.2 Comparative analysis of ALDH in a xenograft and a
syngeneic model for GBM
For future experiments it is necessary to ﬁnd a suitable model with ALDH1A1 and
ALDH1A3 expression. To evaluate a xenograft mouse model and a syngeneic model
for ALDH1A1 and ALDH1A3 expression IHC was performed. Mouse experiments were
done in accordance with the German welfare law. A human PGBM cell line (U87-
MG) and a mouse PGBM cell line (Gl261) were orthotopically implanted into mice as
described in Section 3.2.5.
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Procedure of IHC staining can be found in Section 3. As positive control for both
ALDH isoforms in IHC analysis served a mouse liver (C57BL/6JRj, Figure 4.17).
4.2.1 U87-MG xenograft model
The U87-MG cells are ALDH1A3 positive and ALDH1A1 negative according to The
Human Protein Atlas (Uhlén et al., 2005) and veriﬁed in cell pellet analysis shown
in Figure 4.18.
The U87-MG cells implanted orthotopically into a NMRI-nude mice do not grow
inﬁltrative. The tumour consists of pleomorphic cells with irregular shaped nuclei
and numerous mitosis. The histopathological examination revealed no neovascular-
isation or necrotic areas within the tumour. Macroscopical screening of the animals
for metastasis were negative.
In the histopathologically analysed mouse brains, however, no cell can be found
positively stained for ALDH1A1. The immunoreactivity for ALDH1A3 is non-uniform.
In the group of disulﬁram treated mice (n = 7); 3 mice show no reactivity, 2 show
scattered positively stained tumour cells, and 2 show more than 50% immunoreac-
tivity for ALDH1A3 (Figure 4.19). In the untreated control group (n = 7) two mice
developed no tumour. The tumour of the other mice consist of scattered positively
stained tumour cells for ALDH1A3 and none for ALDH1A1.
4.2.2 Gl261 syngeneic model
The Gl261 cells implanted orthotopically into a C57BL/6JRj mice show cellular pleo-
morphism and irregular shaped nuclei. Neovascularisation is frequently found within
the tumour. No necrotic areas can be found due to tumour size. The tumour did
not grow inﬁltrative and did not metastasise in other organs.
There is no characterisation of Gl261 in terms of ALDH isotype expression. The
(a) ALDH1A1 (b) ALDH1A3
Figure 4.17: IHC, 200 x, ALDH1A1 and ALDH1A3. The mouse liver (C57BL/6JRj) served
as positive control for both ALDH antibody.
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(a) ALDH1A1 (b) ALDH1A3
Figure 4.18: IHC, 200 x, ALDH1A1 and ALDH1A3. U87-MG PGBM cells show no IHC
expression for ALDH1A1 but high expression for ALDH1A3.
(a) ALDH1A1 (b) ALDH1A3
Figure 4.19: IHC , ALDH1A1 200 x and ALDH1A3 400 x. IHC expression in a NMRI-
nude mouse with implanted U87-MG PGBM cells. No IHC expression for ALDH1A1 but
high expression for ALDH1A3.
Figure 4.20: H&E, 200 x. Section of Gl261 PGBM cells implanted into a C57BL/6JRj
mice.
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cell pellet of Gl261 stains positively for ALDH1A3, but is negative for ALDH1A1 (Fig-
ure 4.21). The implanted Gl261 cell show light immunoreactivity for ALDH1A3 (Fig-
ure 4.22). ALDH1A1 expression was not detectable.
(a) ALDH1A1 (b) ALDH1A3
Figure 4.21: IHC 200 x, ALDH1A1 and ALDH1A3. Gl261 PGBM cells do not express
ALDH1A1 but ALDH1A3.
4.3 Evaluation of ALDH isoforms in rat GBM cells
The rat GBM cell line C6 and F98 were analysed for ALDH expression as well. IHC
was performed according to the protocol (Section 3). A rat (Wistar) liver served
as positive control for ALDH1A1 and ALDH1A3. Stained rat GBM cells show IHC
reactivity against ALDH1A3 but not against ALDH1A1 (Figure 4.23, 4.24).
(a) ALDH1A1 (b) ALDH1A3
Figure 4.22: IHC, 200 x, ALDH1A1 and ALDH1A3. ALDH expression in an C57BL/6JRj
mouse with implanted Gl261 PGBM cells.
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(a) rat liver
(b) C6 (c) F98
Figure 4.23: IHC, ALDH1A1. ALDH1A1 expression of rat liver (100 x), C6 (200 x), and
F98 (200 x) GBM cells. The rat (Wistar) liver served as positive control for ALDH1A1
AB. C6 and F98 do not show any reactivity to the ALDH1A1 antibody.
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(a) rat liver
(b) C6 (c) F98
Figure 4.24: IHC, ALDH1A3 expression of rat liver (100 x), C6 (200 x), and F98 (200 x)
GBM cells. The rat (Wistar) liver served as positive control for the ALDH1A3 AB. C6
and F98 show a great reactivity to the ALDH1A3 antibody.
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4.4 Immunohistochemistry analysis of ALDH expression in
canine GBM
As a investigative approach two biopsies of Cocker Spaniel and one German Shepherd
dog are analysed for ALDH1A1 and ALDH1A3 expression. The Cocker Spaniels is
female and 12 years old. From the German Shepherd age and sex is unknown. GBM
in dogs are rare and because they occasionally under go surgery. Both biopsies show
necrosis, neovascularisation, and cellular pleomorphism (Figure 4.25). Numerous
mitotic ﬁgures can be found.
Biopsies were analysed with the same antibody as the human PGBM patients
cohort (Table 3.5). Analysis is possible because proteins are up to 93% (ALDH1A3)
identical. Canine liver served as control for the isotype speciﬁc AB against ALDH1A1
and ALDH1A3 (Figure 4.26). IHC staining was carried out according to the protocol
(Section 3). ALDH1A3 IHC expression was detected in large parts of the GBM tumours
(Figure 4.26). Preponderantly tumour cells stained positive for ALDH1A3. ALDH1A1
expression was not found in one of the cases (Figure 4.26).
(a) German Shepherd dog (b) Cocker Spaniel
Figure 4.25: H&E, 50 x. Sections of canine GBM samples: a) German Shepherd dog
unknown sex and age. b) 7 years old, female Cocker Spaniel.
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(a) ALDH1A1 (b) ALDH1A3
(c) ALDH1A1 (d) ALDH1A3
(e) ALDH1A1 (f) ALDH1A3
Figure 4.26: IHC, ALDH1A1 and ALDH1A3. a + b) Liver of a 6 months old pug as
positive control for ALDH1A1 and ALDH1A3 (50 x). c + d) German Shepherd dog
(100 x) e + f) Cocker Spaniel (100 x). Canine GBM show no ALDH1A1 expression but
ALDH1A2 positive cells are distributed among the tumour cells.
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5.1 Analysis of the distribution of ALDH in human PGBM
Glioblastoma multiforme is one of the most devastating diseases. 15 months after
diagnosis, despite all therapy, only half of the patients are still alive. PGBM are
normally resected and afterwards treated with TMZ and radiotherapy. Due to the
morphology of the tumour, a complete resection is rarely achieved. To understand
PGBM CSC and their ability to evade therapy, it is essential to learn more about
genetic alterations and molecular markers. In this thesis, the ALDH isoform speciﬁc
expression in GBM tissue was analysed with IHC and RT-PCR. The ﬁndings point
out that there is a striking need of isotype speciﬁc investigations.
5.1.1 Primary PGBM
ALDH1A3 is a marker for tumour cells and ALDH1A1 is a marker for reactive astro-
cytes. This is supported by the staining pattern of ALDH1A1 and ALDH1A3 and the
performed double IFC with Ki67. ALDH1A1 positive cells were found more often in
the tumour adjacent region than in the tumour itself, in accordance to Xu et al.
(2015b).
ALDH1 The observations in this thesis show a correlation between ALDH1 IHC ex-
pression and patient survival (Figure 4.6, p. 36). Cox regression analysis revealed
that ALDH1 negative patients live longer than positive patients (odds ratio 3.06, p =
0.0042, adjusted for age). The presented ﬁndings are in accordance with Schäfer et al.
(2012) showing that ALDH1 is an independent marker for PGBM outcome. Only data
published by Adam et al. (2012), suggesting ALDH1 as a prognostic maker for better
outcome of GBM patients, stays in contrast. Adam et al. (2012) analysed 56 tumour
resections and 37 biopsies of GBM patients, without diﬀerentiation by IDH muta-
tion between PGBM and SGBM and with diﬀerent therapy regimens. Altogether, the
comparability of these studies to the observation in this thesis is limited and has to
be elucidated in further investigations.
ALDH1A1 A clear correlation of the survival of ALDH1A1 positive and negative pa-
tients could not be observed in this thesis (Figure 9.1, p. 70). The MOS of ALDH1A1
positive and negative patients suggests a correlation, but this could be only by
chance (odds ratio 1.23, p = 0.43). Campos et al. (2011) report of an increased
intratumoural retinoid availability and ALDH1A1 overexpression, associated with an
unfavorable outcome of GBM patients. This stays in contrast to the function of
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ALDH1A1 in RAS as a pro-diﬀerentiation enzyme, leading to cells, which should be
sensitive to chemo- and radiotherapy. In acute promyelocytic leukemia, for exam-
ple, patients are treated with RA and achieve a complete remission in 70%. RA
targets PML, a retionoic acid receptor fusion protein, and is therefore regarded as
molecular-targeted therapy. PML expression is inversely correlated with cell prolif-
eration in acute promyelocytic leukemia as well as in GBM (Iwanami et al., 2013).
Former ex vivo and in vivo studies showed inhibition of GBM CSC tumour growth and
xenograft mouse model tumours when treated with RA (Campos et al., 2011, 2010).
Mouse tumours showed moderate signs of angiogenic activity, impaired migration,
and growth inhibition. GBM CSC treated with RA showed higher diﬀerentiation com-
pared to untreated CSC. However, preclinical trials with RA given to GBM patients,
only including those with recurrent disease, show only limited eﬀects (Defer et al.,
1997; Kaba et al., 1997; Phuphanich et al., 1997). In a phase II study, promising
eﬀects can be seen, using 13-cis retinoic acid for long time treatment (Wismeth
et al., 2004). Further studies determining the mechanism of PML promoting drug
resistance in GBM and the seemingly inconclusive role of ALDH1A1 in RA are needed.
ALDH1A3 Another result presented in this thesis (Figure 9.2, p. 70) shows a dif-
ference in MOS of PGBM patients with and without ALDH1A3 expression, although
not statistically signiﬁcant (odds ratio 1.17, p = 0.59). This analysis was performed
to substantiate Mao et al. (2013) and Ni et al. (2015) ﬁndings that ALDH1A3 is a
predictive marker for MOS of PGBM. In the single center study of Ni et al. (2015), a
correlation between both the promoter methylation of ALDH1A3 and the IHC expres-
sion, and a longer survival of GBM patients was found. Limitations of their study
are the diﬀerences in treatment of the analysed GBM patients and the uniﬁed evalu-
ation of PGBM and SGBM patients. In this thesis, only PGBM patients were analysed
with the same treatment, but no signiﬁcant prognostic correlation of ALDH1A3 and
MOS of patients was observed. An increase of observations and a separate analysis
of SGBM is intended to validate or reject the supposed diﬀerences. With the help
of transcriptome array analyses, Mao et al. (2013) investigated low and high grade
gliomas and saw an increase of the latter in ALDH1A3 expression. Furthermore, a
signiﬁcant up regulation of ALDH1A3 was associated with the MES subtype and a
down regulation in PN GBM. Pharmacological inhibition of ALDH1 or shRNA knock-
down of ALDH1A3 attenuates PN to MES transformation and in vitro growth of MES
GBM CSC (Mao et al., 2013).
Long time survivors
Long time survivors are interesting for research because of the obvious diﬀerence to
the shorter living patients (Section 4.1.1). The separate analysis of PGBM long term
survivors (n = 11) in this thesis did not show any distinction for shorter living PGBM
patients in ALDH IHC expression. A genomic alteration or diﬀerence in metabolism
leading to this advantage in therapy response has not yet been found. Indications of
altered signaling pathways have been described lately by Fazi et al. (2015), showing
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that long time survivors (n = 4) diﬀer in TGF-β expression compared to shorter
living PGBM patients (n = 9). A collection of a larger cohort of long time survivors
could reveal more information about beneﬁcially altered signaling.
Gender analysis
Gender diﬀerences in incidence, like in GBM, and progression of human disease
are mechanistically important to understand varying response to treatment. In
metabolic diseases, inﬂammation, and some cancers, sex-speciﬁc divergences are ob-
served. The results presented in this thesis (Section 4.1.1) suggest a diﬀerence of
female and male patients in terms of ALDH1A1 IHC expression, next to the described
ALDH1 correlation to survival (Figure 4.8). Female patients signiﬁcantly proﬁt from
the lack of ALDH1A1 expression (odds ratio 2.81, p = 0.048), while men seem not to
be inﬂuenced by this isotype (Figure 4.9). The multiple Cox regression analysis after
adjusting to the age showed that double positive for ALDH1A1 and ALDH1A3 female
PGBM patients even have a risk of disease progression with a hazard ratio 3.6 (p =
0.018). The reasons for this gender diﬀerences in PGBM are unknown. Observations
of other diseases suggest that estrogen inﬂuences the expression of ALDH1A1, sup-
presses ALDH1A2 and ALDH1A3, following a female-speciﬁc mechanism of retionoic
acid signaling (RAS) (Petrosino et al., 2014). The RAS pathway, for example in adi-
pose tissue, is described to be inﬂuenced by estrogen. In breast cancer, Isfoss et al.
(2013) could show an increased ALDH1A1 positive cell proportion in breast ductules
in women with a familial risk for breast cancer. As estrogen regulated ALDH expres-
sion is tissue dependent (Duester et al., 2003); a possible eﬀect on PGBM tumour
cells cannot be excluded. Another explanation for the observed correlation could
be found in studies of neurodegenerative diseases showing a protective action of
estradiol and estrogen receptors in the female and male brain. These receptors are
cooperating in multiple signaling mechanisms (Arevalo et al., 2015; Dhandapani and
Brann, 2002; Hatch et al., 2005). Aromatase, the enzyme that converts androgens
into estrogens, is physiologically expressed in neurons from diﬀerent brain regions
and is rapidly regulated (Cornil et al., 2012). After brain injury, however, reac-
tive astrocytes show increased aromatase expression, reducing reactive gliosis and
protecting neurons (Azcoitia et al., 2001; McCullough et al., 2003). Estrogen recep-
tor α, estrogen receptor β, and G protein-coupled estrogen receptor trigger parallel
neuroprotective mechanisms by activation of extracellular signal-regulated kinase 1
and 2 as well as phosphatidylinositide 3-kinases signaling and pro-apoptotic c-Jun
N-terminal kinase signaling (Wu et al., 2005; Yang et al., 2010; Zhao and Brinton,
2007). However, most knowledge of neuroprotective estrogen signaling is only based
on acute models of neurodegeneration. Data on continuous inﬂuences of female
hormones in chronic, slowly progressing diseases is missing. A large cohort study
suggests that only exogenous hormones have a protective eﬀect on gliomas (Felini
et al., 2009). The data presented in this thesis, the gender separated analysis, shows
striking diﬀerences between female and male in survival and ALDH1A1 IHC expres-
sion in PGBM samples (Figure 4.9). In general, the MOS of female and male PGBM
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patients diﬀer by 144 days (Table 3.3). Furthermore, female ALDH1A1 positive pa-
tients live shorter than female ALDH1A1 negative patients (Figure 4.9). In former
ALDH studies, the diﬀerentiation between male and female human PGBM was not
analysed. Only one orthotopic GBM rat model identiﬁes a survival advantage of
female, estrogen treated, ovariectomized nude rats (Plunkett et al., 1999). In the
future, the four core genotypes model could help to ﬁnd out if sex chromosome or
gonadal hormones are responsible for the observed gender diﬀerences (Arnold and
Chen, 2009; De Vries et al., 2002). With the help of this model, answers to the
question if gender diﬀerences are associated with neuroprotective mechanisms or if
ALDH interferes with estrogen in RAS like in adipose tissue, due to the chromosomal
inﬂuences, or due to random chance, might be found. GBM subtype speciﬁc analysis
showed that males are categorized more often into the MES subtype than female
patients (Sun et al., 2014). Furthermore, male MES GBM astrocytes showed greater
growth and colony forming capacity than female ones and could be correlated to
retinoblastoma signaling inactivation. MES GBM are in general the unfavourable
subtype, being insensitive to standard therapy. The in this thesis presented data
presented was not subclassiﬁcated and can therefore not be compared to the data
from Sun et al. (2014). In general, a subclassiﬁcation based on biopsies or small
tumour samples is not representative for the whole tumour and is usually made
without respect to the heterogenous nature of GBM. Therefore, subclassiﬁcation of
PGBM was not performed in this thesis.
MGMT and diﬀerent IHC expression of ALDH1 subtypes
The hypothesis that MGMT promoter methylation status and ALDH1 IHC expression
are independent markers for MOS of PGBM is corroborated with the data presented
in this thesis (Section 4.1.3). Following new recommendations, the cut-oﬀ for the
MGMT promoter methylation status was set to a much lower percentage in this thesis
(Quillien et al., 2012) than in former studies by Schäfer et al. (2012). Corroborating
this well known marker with the presented data indicates representativeness with
respect to MGMT promoter methylation and response to TMZ.
The hypermethylation of ALDH1A3, leading to a low IHC expression of ALDH1A3,
results in a signiﬁcantly favourable outcome of PGBM patients without MGMT pro-
moter methylation (Zhang et al., 2013). The data presented here is leading in the
same direction but requires a higher number of observation to gain signiﬁcance (Fig-
ure 9.11).
RT-PCR of human PGBM samples
The RT-PCR was performed to relevance of ALDH1A1, ALDH1A2, ALDH1A3, ALDH2,
ALDH3A1, ALDH7A1, and ALDH8A1 (p. 41) in PGBM.
No speciﬁc pattern of ALDH expression was seen in analysed microdissected sam-
ples. The mRNA level of ALDH1A3 can be directly associated to the IHC expression.
The ALDH1A1 mRNA levels were surprisingly high with 75% positive PGBM in the
58
5 Discussion
investigated patients. This is evidence for strict post transcriptional or post trans-
lational regulation. The promoter of ALDH1A1 contains a positive regulatory region
(−91 to 53 bp) (Yanagawa et al., 1995), and post translational regulation through
acetylation or deacetylation of lysin was found in breast cancer (Zhao et al., 2014).
A study dealing with PGBM CSC and ALDH regulation has not been performed, but
it can be estimated that regulatory systems could be found.
5.1.2 Secondary PGBM
This thesis challenges the ﬁndings of Schäfer et al. (2012). The claimed change
of the immunoreactive fraction of ALDH1 increase in secondary PGBM compared to
corresponding primary tissue (Table 4.2, p. 38) was not reproduced. This raises the
question if ALDH1 detects CSC or diﬀerentiated cells. Keeping the CSC theory in
mind and the proclaimed insensitivity of CSC to therapy, the equal proportion of
ALDH1 expression in primary and secondary PGBM observed by IHC in this thesis
suggests that the diﬀerentiated cell population expresses ALDH1.
5.1.3 Conclusion of human PGBM analysis
Taken together, the heterogeneity of PGBM is a main complication in GBM studies.
The investigated specimens represent only small pieces and are not from the same
place within the tumours. A comparison of deﬁned tumour regions, or ideally of
whole tumours, could help to ﬁnd the reason for recurrence of PGBM. Another
approach would be a separate analysis of the described subgroups of PGBM tumours.
As proposed by Mao et al. (2013), ALDH1A3 is up-regulated only in MES but not in
PN PGBM.
CSC detection in terms of a reliable routine prognostic marker is usually based on
IHC of FFPE material. ALDH isotype speciﬁc research in PGBM is challenging because
the proteins are up to 70% identical, this is also discussed for breast cancer (Marcato
et al., 2011a). RT-PCR analysis does not give any hint for enzyme activity or relevance
after post transcriptional regulation. A combined analysis with IHC, enzyme activity
measurements (Aldeﬂour), and RT-PCR or methylation assays would give a general
view on ALDH presence on all levels and might help to ﬁnd a new therapy target of
PGBM tumours.
5.2 Evaluation of the syngeneic and the xenograft PGBM
mouse model
In this thesis, a syngeneic and a xenograft orthotopic mouse model were used. The
decision to take an orthotopic model was made because of two reasons: the ortho-
topic implantation of cells enables the host to build up a microenvironment, closely
mimicking the situation seen in humans. Disadvantages, especially with intracranial
models, are that the operation is challenging and a higher animal morbidity than
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in easily performed subcutaneous injection has to be taken into account (Sano and
Myers, 2009). The advantages of the orthotopic model outweigh the disadvantages.
Inoculation of cells into the brain of a mouse is a well established model to investi-
gate neuronal tumours (Ozawa and James, 2010; Yamada et al., 2004). The cranial
hemispheres were chosen for inoculation because, even by a great increase of tumour
volume, epileptic seizures are rarely observed. The stereotactic implantation makes
it possible to securely inject into the parenchyma and not into the ventricles or the
subarachnoid space. For the injection a dulled syringe was used, so brain tissue was
only separated but not punched. The break between injection and removal of the
syringe prevents the cell suspension to be sucked out immediately. No extra cranial
tumour growth could be observed. Injection volume was set to 2μl to minimise brain
pressure increase even though cell suspension is viscous and preparing the syringe
needs some practice. The anaesthesia was well controllable, so no mice was lost
due to anaesthesia. The recovery period after anaesthesia was about 30 min, before
the mice started grooming and eating. The antagonizable anaesthesia with combi-
nation of fentanyl, meditomidin, and midazolam is superior to the use of the long
eﬀective ketamin and xylazin (Flecknell and Mitchell, 1984; Green, 1975; Zuurbier
et al., 2014). The main diﬀerence is the fact that the triple anaesthesia is easy to
handel (Kirihara et al., 2014) and can be antagonised after intervention to minimize
eﬀect on the animals. Postoperative analgesia was performed with Buprenorphin
and showed good eﬀectively, corroborating ﬁndings of Matsumiya et al. (2012). The
intervals between clinical checkups were suﬃcient to see any potential changes in
behavior, appearance, or central nervous system symptoms. Intervention according
to the Table 3.11 was fast and ensured that animals did not suﬀer.
Tumour screening is helpful to identify critical checkpoints or therapeutic eﬀects
during experiment. In subcutaneous tumour models, the use of sliding calliper
is standard. In intracranial models, only an MRI can be performed for a in vivo
measurement of tumour growth. The short isoﬂurane anaesthesia is feasible to
minimize the anaesthetic eﬀect of physiological behavior, though it has an eﬀect on
neurocognitive functions (Liu et al., 2014a). Scanning without immobilizing animals
is not eligible according to animal welfare.
Histopathological workup showed a reasonable tumour uptake, with only 2 mice
without detectable tumor. The tumours were well deﬁned and did not grow into
the injection canal. No metastasis of tumours were found in the syngeneic and the
xenograft models.
5.2.1 ALDH expression in mouse models
The antibody shows a good and speciﬁc staining for ALDH isotypes in the positive
control (liver, Figure 4.17, p. 48). The xenograft and the syngeneic mouse model,
with U87-MG and Gl261 cells, respectively, did not show any ALDH1A1 immunoreac-
tivity (Figures 4.19, 4.22). The analysis of the cells in culture did not show any
ALDH1A1 reactivity as well (Figures 4.18, 4.21). Reactive astrocytes can normally
be found after stroke and brain injury (Bardehle et al., 2013). The reason for this
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activation is unclear. The absence of ALDH1A1 cells in the compared mouse model
approaches can be due to diﬀerent reasons. The reactivation of astrocytes should
have been in the normal brain parenchyma surrounding the artiﬁcial tumour. One
hypothesis for the missing ALDH1A1 expression would be that the immunocompro-
mised status of the mice in xenografts and the low immunogeneic nature of Gl261
cells in C57BL/6JRj do not lead to an activation of astrocytes.
In the xenograft model, the ALDH1A3 staining is scattered throughout the tumours.
While untreated mice only show a small amount of positive cells, two of the DSF
treated mice show a great immunoreactivity. The C57BL/6JRj mice show scattered
positive cells for ALDH1A3 in the Gl261 tumours (Figures 4.19, p. 49, Figure 4.22,
p. 50). Both observations stay in contrast to the cell pellet analysis of the same cells
where cells showed more than 80% reactivity to the ALDH1A3 antibody (Figures 4.18,
4.21). A phenotypical shift between cell culture and in vivo takes place. Diﬀerent
conditions must be the reason.
The presence of ALDH1A3 expression in the DSF treated xenograft mice (n = 7) is
ambiguous. While two mice show only minor reactivity, three no reactivity, and two
mice show an exceptional amount (above 50%) of ALDH1A3 positive cells. These
results are not conclusive. Diﬀerences in this group can be due to the diﬀerent cut-
ting levels of the tumours investigated. The investigated sections show only a small
part of the whole tumour. Serial sections of the tumour would give a complemented
view and may show a diﬀerent distribution of ALDH1A3 expression throughout the
tumour. A functional isotype speciﬁc essay for ALDH isoforms could reveal more
information about the enzyme activity and the actual total number of ALDH1A3
positive cells in cell culture conditions and in vivo growth. However, available as-
says, like the ﬂow cytometric analysis named Aldeﬂuor assay (Jones et al., 1995),
are not isotype speciﬁc.
Further research is needed to understand the meaning of ALDH expression in cell
culture conditions and the lack of expression in mouse experiments.
5.3 Evaluation of rat GBM cells
The C6 and F98 rat GBM cells did not show any speciﬁc immunoreactivity to the
utilised ALDH1A1 antibody, but they did against ALDH1A3 (Figures 4.23, 4.24). An
intracranial implantation into rats would be interesting to see if the phenotypical
shift, observed in mice, is repeatable in rats.
5.4 Evaluation of the canine GBM model
The antibody designed primarily for human material for ALDH1A1 and ALDH1A3
detects the enzymes speciﬁcally as well in canine samples, as shown by the positive
controls used in this study. At least for the small number of investigated samples of
canine GBM, only ALDH1A3 is present in GBM tumour cells (Figure 4.26, p. 54). To
further analyse the relevance of ALDH in canine GBM, it is necessary to increase the
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number of investigations and to provide complete patient data including survival
and therapy.
The natural presence of ALDH1A3 in canine GBM is a scientiﬁc advantage over
the evaluated mouse models. Therefore, dogs are potential candidates for further
ALDH enzyme analysis. One advantage of using dogs in therapeutic studies is the
appropriate size of the scull for surgical resection. Furthermore, dogs develop GBM
spontaneously, allegorizing the events that lead to GBM in humans (York et al.,
2012). The heterogeneity of human tumours in morphology, histology, and growth
pattern is well represented by the canine tumours. In contrast, mouse tumours are
homogenous, highly artiﬁcial, and do not grow inﬁltrative. Another important fac-
tor is that immunologically naive mice do not show comparable immunoreactivity
to tumours as humans or dogs. This is a considerable advantage in favour of canine
models, as the immunological response is targeted by newly developed medications
(Xiong et al., 2010). Genetic alterations of canine GBM are comparable in most
of the cases to the ones found in human GBM (Olin et al., 2014). However using
privately owned dogs has a lot of disadvantages as a model for human GBM: lack
of reproducibility, unclear environmental conditions, non-uniform cohort, and owner
compliance. The costs of preclinical trials would increase because of the scale-up
for producing the required amount of preclinical drugs. An elongation of preclinical
trials to 1 – 3 years, according to Hansen and Khanna (2004), is reasonable to esti-
mate. One successful trial in dogs was done by Stubbs et al. (2002) who evaluated
a new device to deliver brachytherapy to the margins of resected brain tumours.
Irrespective of the potential use of canine GBM models for further research, the
presence of ALDH1A3 expression in canine GBM suggests a preservation of this en-
zyme and its relevance in tumour growth. Dogs could therefore proﬁt from novel
medication targeting ALDH1A3.
Another interesting approach could be a genome analysis of canine GBM patients.
As mentioned, Boxers and Boston Terriers are over represented in canine GBM pa-
tients (Beveridge and Sobin, 1974; Snyder et al., 2006). A breed-based analysis,
as done for other diseases (Erich et al., 2013), could reveal interesting genetic al-
terations. The genetic pool of the dog breeds is preserved by the strictly closed
breeding programs in order to get typical phenotypes (Davis and Ostrander, 2014).
Hence, the number of deleterious alleles in a single dog breed is limited (Karlsson
et al., 2007). In this respect, dog breeds allegorise the outbred mouse stocks in terms
of heterogeneity. These characteristics make pet dogs ideal models, with the above
mentioned restrictions, to analyse genetic driver mutations and to test preclinical
medications.
5.5 Conclusion of animal model analysis
Summing up, the ability to use the same antibody for human, murine, rat, and canine
samples made it possible to directly compare results. However, the suitability of the
presented rodent models for ALDH isotype speciﬁc research is not satisfactory. There
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is a need to understand why ALDH1A3 is important for the survival of the GBM cells
in culture, but expression is down regulated after implantation. ALDH1A1 expression
does not seem to be important for rat and mouse GBM cells in cell culture conditions.
In any case, the results indicate that ALDH1A3 is more important for GBM CSC than
ALDH1A1.
The absence of typical ALDH1A1 staining pattern for reactive astrocytes in the
investigated mice with a implantation of murine and human GBM cells gives rise
to more questions than answers. In canine samples, ALDH1A1 was absent as well.
Hypotheses could be: no reactivation of astrocytes takes place, or reactive astrocytes
of mice and dogs do not express ALDH1A1.
The reported ALDH1A3 expression in canine GBM is promising and will be investi-
gated in more samples to substantiate ﬁndings. The canine ALDH1A3 immunohisto-
chemical expressions of tumour cells indicate another similarity, next to the known
parallels to the human GBM counterpart.
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Recapitulating the results presented in this thesis, ALDH1A1 immunohistochemical
expression is associated with the reactive astrocyte staining pattern while ALDH1A3
immunohistochemical expression is more related to the tumour cells.
MOS of PGBM patients can only be predicted with ALDH1. Gender separated
analysis of human PGBM for ALDH1 immunohistochemical expression revealed an
unexpected diﬀerence in prognostic value of isotypes. Female PGBM patients with a
combination of ALDH1A1 and ALDH1A3 live signiﬁcantly shorter than double negative
female PGBM patients. The mentioned four core genotypes model (Arnold and Chen,
2009; De Vries et al., 2002) could substantiate ﬁndings and help to understand the
gender-speciﬁc preponderance and value of ALDH expression in GBM.
The number of canine GBM samples analysed for ALDH1 expression has to be
increased in further research. However, found similarities of human and canine
GBM can help to understand more about ALDH1A3 functions and improve therapy
of canine GBM. Moreover, dogs could serve as a good model for human PGBM in the
future, naturally expressing ALDH1A3 in tumour cells.
The mouse models investigated in this thesis seem not to be suitable to reproduce
the whole situation for ALDH1 expression in human PGBM. A rat orthotopic GBM
model with the characterized C6 and F98 cells is a possible alternative. Moreover, it
would be interesting to see whether rat cells also change expression proﬁle between
in vitro and in vivo conditions, as observed for GL261 and U87-MG cells. This rat
model would also be a syngeneic approach, the presence or absence of ALDH1A1
expressing cells in IHC will be interesting.
The perfect model for ALDH expression in GBM has not yet been found. An
easy method to survey ALDH enzyme activity can be the inoculation of PGBM cells
into the chicken chorioallantoic membrane (Strojnik et al., 2010). In principle, this
model stands out with high turn over rates (7 days), inexpensiveness, comparable
expression of immunohistochemical markers, and less ethical concerns than mouse
and rat experiments. A comparison to human GBM is missing and would reﬁne this
model.
To sum up, the data presented data on human, mouse, rat, and canine GBM sam-
ples, emphasize the necessity of isotype speciﬁc ALDH research. Though proteins
are up to 70% identical, results indicate that the diﬀerent isotypes carry out di-
verse functions. Diﬀerences in expression of ALDH in vitro and in vivo conditions
impede the transfer of research. Reasonable and convincing explanations for this
phenomenon are only speculative. To gain further expertise in ALDH expression, cell
culture research and animal model based investigations are needed. However, these
are dependent on further characterisation of enzyme activity, knowledge about the
functional diﬀerences of ALDH isotypes, and better isotype speciﬁc analytic methods.
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Glioblastoma multiforme (GBM) is the most common malignant primary brain tu-
mour in adults with a median survival, despite of multimodal aggressive therapy, of
only 15 months. Relapse occurs inevitably because of the inﬁltrative nature of GBM.
To date, only the MGMT promoter methylation is a reliable marker for therapy sen-
sitivity. Survival-associated prognostic factors as well as novel therapy targets are
urgently needed. Multiple genetic and metabolic pathway alterations contribute to
tumour progression and therapy resistance. Recently proposed CSC markers for solid
cancers include the aldehyde dehydrogenase (ALDH) superfamily. This cytoplasmic
enzyme family consists of 19 diﬀerent isoforms. The ALDH enzymes act upon oxida-
tive stress and participate in proliferation, diﬀerentiation, and cell cycle arrest. The
evolutionary conservation of the protein family enables comparative considerations
of diﬀerent species.
In the presented study, isotype speciﬁc expression of ALDH is analysed in human
GBM tumours and in two commonly used mouse GBM models. Expression of ALDH
in the mouse models is then compared with the human GBM to ﬁnd a suitable model
for further research.
The presented results indicate that there is, though challenging, a necessity for
isotype speciﬁc analysis of ALDH expression. ALDH1A1 immunohistochemical expres-
sion in human PGBM was found primarily in the tumour adjacent region, whereas
ALDH1A3 positive cells were more frequently found among tumour cells. Prognostic
relevance for PGBM patients’ outcome was found for the ALDH1 immunohistochem-
ical expression. Moreover, female PGBM patients were shown to have prolonged
survival if neither ALDH1A1 nor ALDH1A3 expression is present. For male PGBM
patients, ALDH1A1 and ALDH1A3 immunohistochemical expression could not be cor-
related to the medium overall survival. The reasons for this gender diﬀerence remain
yet undetermined.
Both the murine and the human GBM cells analysed in this thesis did not show
ALDH1A1 immunohistochemical expression in cell culture or after implantation. The
expression of ALDH1A3 is inhomogeneous in the analysed groups, raising further
questions, which will be investigated in the future.The investigative approach of
this thesis showed that the analysed canine GBM samples express ALDH1A3 but not
ALDH1A1. This diﬀerence to human PGBM tumours in ALDH expression can help to
understand more about the metabolic processes in tumour cells and the reactions
to the tumour cells in the surrounding tissue.
Finally, there are two particularly promising research subjects for future investi-
gations: the gender speciﬁc prognostic power of ALDH expression in PGBM patients
and the reason for the change in ALDH1A3 expression between in vitro and in vivo
conditions. This knowledge can contribute to ﬁnding new targets for PGBM therapy
and to prolonging patient survival.
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8 Zusammenfassung
Das Glioblastoma multiforme (GBM) ist der häuﬁgste maligne hirneigene Tumor des
erwachsenen Menschen, mit einem mittleren Überleben, trotz aggressiver multimo-
daler Therapie, von nur 15 Monaten. Aufgrund der inﬁltrativen Natur des GBM tre-
ten Rezidive unvermeindlich auf. Zur Zeit gibt es nur einen zuverlässigen Marker für
das Ansprechen der Therapie, die MGMT Promoter Methylierung. Mit dem Über-
leben assoziierte Marker und neue Therapieziele werden dringend benötigt. Viele
genetische und metabolische Veränderungen führen zu Tumorwachstum und Thera-
pieresistenz. Zu den vorgeschlagenen neuen Markern für CSC der soliden Tumoren
gehört die Aldehyddehydrogenase-Superfamilie (ALDH-Superfamilie). Diese Enzym-
familie besteht aus 19 verschiedenen, im Zytoplasma lokalisierten Isoformen. Die
ALDH-Enzyme sind beteiligt an der Reaktion auf oxidativen Stress, an Prolifera-
tion, Diﬀerenzierung, und Zellzyklus-Arrest. Die evolutionäre Konserviertheit der
Proteinfamilie lässt eine vergleichende Betrachtung zwischen verschiedenen Spezies
zu.
Diese Arbeit vergleicht isotypenspeziﬁsch die ALDH Expression von menschlichen
GBM Tumoren mit zwei weitverbreiteten Tierversuchssmodellen. Die ALDH Expres-
sion der Maustumoren wird verglichen mit der der menschlichen GBM, um für zu-
künftige Untersuchungen ein geeignetes Modell zu ﬁnden.
Die vorliegenden Resultate deuten darauf hin, dass die isotypenspeziﬁsche Analyse
der ALDH notwendig, jedoch herausfordernd ist. Die immunhistochemische Expres-
sion von ALDH1A1 in humanen GBM Tumoren wurde hauptsächlich in der an den
Tumor angrenzenden Region detektiert, während ALDH1A3 positive Zellen häuﬁger
unter den Tumorzellen gefunden wurden. Eine prognostische Relevanz für das Über-
leben der PGBM Patienten konnte für die ALDH1 Expression nachgewiesen werden.
Darüber hinaus zeigte sich, dass weibliche PGBM Patienten einen Überlebensvor-
teil haben, falls weder ALDH1A1 noch ALDH1A3 Expression vorliegt. Für männliche
PGBM Patienten konnte keine Korrelation der ALDH1A1 und ALDH1A3 Expression
mit der mittleren Überlebenszeit gefunden werden. Die Gründe für die geschlechts-
speziﬁschen Unterschiede sind unbekannt und bedürfen weiterer Forschung.
Die in der vorliegenden Arbeit untersuchten murinen und humanen GBM Zellen
zeigten in der Zellkultur und nach Implantation keine ALDH1A1 Expression. Die
Expression von ALDH1A3 ist uneinheitlich in den untersuchten Gruppen, welches
neue Fragen aufwirft, die in späteren Studien untersucht werden sollen. Die hier
durchgeführte investigative Untersuchung von caninen GBM Tumoren zeigte, dass
nur ALDH1A3, nicht jedoch ALDH1A1 exprimiert wird. Dieser Unterschied in der
ALDH Expression zum menschlichen PGBM kann in weiteren Studien helfen, die
metabolischen Prozesse im Tumor und die Reaktion des umliegenden Gewebes auf
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die Tumorzellen besser zu verstehen.
Abschließend sind im Hinblick auf weitere Untersuchungen vor allem zwei viel-
versprechende Ansatzpunkte zu nennen: die geschlechtsspeziﬁsch unterschiedliche
Eignung der ALDH Expression in PGBM als prognostischer Marker sowie die Ur-
sache für die Veränderung der ALDH1A3 Expression zwischen in vitro und in vivo
Bedingungen. Das gewonnene Verständnis kann in der Zukunft benutzt werden, um
Angriﬀsziele für neue PGBM Therapien zu ﬁnden und zu einer Verlängerung des
Lebens von Patienten beizutragen.
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Table 9.1: Clinical characteristics of GBM patients enrolled in this study
Patient No sex age at time of diagnosis survival days relapse free survival
1 m 56 1263 791
2 m 39 357 183
7 m 79 410
8 f 47 362 220
9 m 50 974 613
10 m 64 2112 606
11 f 69 391 150
13 m 62 673 626
17 m 58 259 179
18 m 62 2904 159
22 m 62 442 369
25 f 56 631 383
27 m 49 870 219
30 f 50 373 238
31 f 50 258 139
32 f 57 1437 16
40 f 50 1137 606
41 m 42 2124 1658
42 m 74 219 133
44 m 20 779 515
45 f 42 1707 24
47 m 53 933
49 m 68 933 414
50 f 55 498 402
53 m 70 374 92
54 f 48 1201 721
57 m 63 664 531
58 m 42 473 110
65 f 55 784 525
67 m 65 572 454
76 m 59 623 293
88 m 66 550 290
91 f 69 1058 555
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Table 9.1: Clinical characteristics of PGBM patients enrolled in this study
Patient No sex age at time of diagnosis survival days relapse free survival
95 m 53 483 292
96 m 62 289
97 m 76 446
98 f 78 78
99 m 74 172
100 f 50 411
101 f 70 93
102 f 71 37
103 f 78 110
104 f 68 74
106 f 66 169
107 m 79 22
108 f 50 768
109 f 40 89
112 m 62 206
113 m 31 342
114 f 65 463
115 m 56 261
116 m 48 366
117 m 79 121
118 f 73 398
119 m 67 280
120 m 45 345
121 f 55 357
122 f 55 448
123 f 71 603
124 m 33 645
125 m 70 517
126 m 47 623
128 m 53 107
129 f 63 117
130 m 77 249
131 m 71 69
132 f 70 329
133 f 72 48
134 m 80 45
69
9 Supplemental Data
0 500 1000 1500 2000 2500 3000
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
days
su
rv
iva
lp
ro
ba
bi
lit
y
ALDH1A1 negative
ALDH1A1 positive
Figure 9.1: Survival of patients with diﬀerent ALDH1A1 expression in primary PGBM.
ALDH1A1 positive (n = 22) with a MOS of 382 days, ALDH1A1 negative (n = 43) with
a MOS of 446 days.
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Figure 9.2: Survival of patients with diﬀerent ALDH1A3 expression in primary PGBM.
ALDH1A3 positive (n = 49) with a MOS of 373 days, ALDH1A3 negative (n = 16) with
a MOS of 495 days.
70
9 Supplemental Data
0 500 1000 1500
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
days
RF
S
pr
ob
ab
ilit
y
ALDH1 negative
ALDH1 positive
Figure 9.3: RFS with diﬀerent ALDH1 expression in primary PGBM. ALDH1 positive
(n = 20) with a medium RFS of 291 days, ALDH1 negative (n = 8) with a medium
RFS of 338 days.
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Figure 9.4: RFS with diﬀerent ALDH1A1 expression in primary PGBM. ALDH1A1
positive (n = 11) with a medium RFS of 290 days, ALDH1A1 negative (n = 17) with
a medium RFS of 383 days.
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Figure 9.5: RFS with diﬀerent ALDH1A3 expression in primary PGBM. ALDH1A3
positive (n = 19) with a medium RFS of 382 days, ALDH1A3 negative (n = 9) with
a medium RFS of 219 days.
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Figure 9.6: Survival of patients with diﬀerent ALDH1 expression in secondary PGBM.
ALDH1 positive patients (n = 21) have a MOS of 550 days compared to ALDH1
negative patients (n = 7) with a MOS of 870 days.
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Figure 9.7: Survival of patients with diﬀerent ALDH1A1 expression in secondary
PGBM. ALDH1A1 positive patients (n = 12) have a MOS of 590 days compared to
ALDH1A1 negative patients (n = 16) with a MOS of 644 days.
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Figure 9.8: Survival of patients with diﬀerent ALDH1A3 expression in secondary
PGBM. ALDH1A3 positive patients (n = 22) have a MOS of 627 days compared to
ALDH1A3 negative patients (n = 6) with a MOS of 721 days.
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(a) female
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(b) male
Figure 9.9: Survival of PGBM patients separated by sex and ALDH1A3 expression.
female: ALDH1A3 positive (n = 21) have a MOS of 373 days ALDH1A3 negative (n = 5)
have a MOS of 391 days. male: ALDH1A3 positive (n = 28) have a MOS of 370 days
ALDH1A3 negative (n = 11) have a MOS of 623 days.
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(a) MGMT promoter methylated
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(b) MGMT promoter not methylated
Figure 9.10: Survival of patients with or without MGMT promoter methylation in
combination with ALDH1A1 expression in primary PGBM. With MGMT promoter
methylation ALDH1A1 positive patients (n = 9) have a MOS of 373 days compared to
ALDH1A1 negative patients (n = 15) with a MOS of 664 days. No MGMT promoter
methylation ALDH1A1 positive patients (n = 13) have a MOS of 391 days compared
to ALDH1A1 negative patients (n = 28) with a MOS of 350 days.
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(a) MGMT promoter methylated
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(b) MGMT promoter not methylated
Figure 9.11: Survival of patients with and without MGMT promoter methylation in
combination with ALDH1A3. With MGMT promoter methylation ALDH1A3 positive
patients (n = 21) have a MOS of 498 days compared to ALDH1A3 negative patients
(n = 3) with a MOS of 664 days. No MGMT promoter methylation ALDH1A3 positive
patients (n = 28) have a MOS of 344 days compared to ALDH1A3 negative patients
(n = 13) with a MOS of 473 days.
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Table 9.2: MGMT and ALDH1A1
ALDH1A1
positive negative
MGMT promotor methylated 9 15
MGMT promoter not methylated 13 28
Table 9.3: MGMT and ALDH1A3
ALDH1A3
positive negative
MGMT promotor methylated 21 3
MGMT promoter not methylated 28 13
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Table 9.4: Results of RT-PCR
ALDH
Patients No. GFAP GAPDH 1A1 1A2 1A3 2 3A1 7A1 8A1
1 + + + − + − − + −
2 + + + + + − − − −
8 + + + + + − − + −
9 + + + − − − − + −
10 + + + − − − − − −
13 + + − − + − − − −
17 + + − − + − − + −
25 + + + + + + − + −
30 + + + + + + − − −
32 + + − + + + − + −
41 + + + + + − + − −
42 + + + − + − − − −
44 + + − − + − − + −
47 + + + − − − − − −
49 + + + − + − − + +
50 + + − − + − − − −
53 + + + − + − − − −
57 + + − − − − − − −
65 + + + − − − − − −
67 + + + + − − − − −
71 + + + − + − − − −
88 + + + − − − − − −
91 + + + − + − − − −
95 + + + − + − − + −
number of positive patients 23 23 17 8 15 3 1 8 1
78
Bibliography
S. A. Adam, O. Schnell, J. Pöschl, S. Eigenbrod, H. A. Kretzschmar, J. C. Tonn,
U. Schüller, ALDH1A1 is a marker of astrocytic diﬀerentiation during brain devel-
opment and correlates with better survival in glioblastoma patients. Brain Pathol,
22 (6), 788–97, 2012.
C. Aliﬁeris, D. T. Trafalis, Glioblastoma multiforme: Pathogenesis and treatment.
Pharmacol Ther, 152, 63–82, 2015.
M. A. Arevalo, I. Azcoitia, L. M. Garcia-Segura, The neuroprotective actions of
oestradiol and oestrogen receptors. Nat Rev Neurosci, 16 (1), 17–29, 2015.
A. P. Arnold, X. Chen, What does the "four core genotypes" mouse model tell us
about sex diﬀerences in the brain and other tissues? Front Neuroendocrinol, 30 (1),
1–9, 2009.
A. Arshad, B. Yang, A. S. Bienemann, N. U. Barua, M. J. Wyatt, M. Woolley,
D. E. Johnson, K. J. Edler, S. S. Gill, Convection-enhanced delivery of carbo-
platin PLGA nanoparticles for the treatment of glioblastoma. PLoS One, 10 (7),
e0132266, 2015.
J. I. Ausman, W. R. Shapiro, D. P. Rall, Studies on the chemotherapy of experi-
mental brain tumors: development of an experimental model. Cancer Res, 30 (9),
2394–400, 1970.
I. Azcoitia, A. Sierra, S. Veiga, S. Honda, N. Harada, L. M. Garcia-Segura, Brain
aromatase is neuroprotective. J Neurobiol, 47 (4), 318–329, 2001.
S. Bao, Q. Wu, R. E. McLendon, Y. Hao, Q. Shi, A. B. Hjelmeland, M. W. Dewhirst,
D. D. Bigner, J. N. Rich, Glioma stem cells promote radioresistance by preferential
activation of the DNA damage response. Nature, 444 (7120), 756–60, 2006.
S. Bardehle, M. Krüger, F. Buggenthin, J. Schwausch, J. Ninkovic, H. Clevers, H. J.
Snippert, F. J. Theis, M. Meyer-Luehmann, I. Bechmann, L. Dimou, M. Götz,
Live imaging of astrocyte responses to acute injury reveals selective juxtavascular
proliferation. Nat Neurosci, 16 (5), 580–586, 2013.
C. M. Becker, R. K. Oberoi, S. J. McFarren, D. M. Muldoon, D. H. Pafundi, J. L.
Pokorny, D. H. Brinkmann, J. R. Ohlfest, J. N. Sarkaria, D. A. Largaespada, W. F.
Elmquist, Decreased aﬃnity for eﬄux transporters increases brain penetrance and
molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma.
Neuro Oncol, 17 (9), 1210–1219, 2015.
79
Bibliography
Z. Belcaid, J. A. Phallen, J. Zeng, A. P. See, D. Mathios, C. Gottschalk, S. Nicholas,
M. Kellett, J. Ruzevick, C. Jackson, E. Albesiano, N. M. Durham, X. Ye, P. T.
Tran, B. Tyler, J. W. Wong, H. Brem, D. M. Pardoll, C. G. Drake, M. Lim, Focal
radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields
long-term survival and a protective antigen-speciﬁc memory response in a murine
glioma model. PLoS One, 9 (7), e101764, 2014.
M. Bettstetter, S. Dechant, P. Ruemmele, C. Vogel, K. Kurz, M. Morak, G. Keller,
E. Holinski-Feder, F. Hofstaedter, W. Dietmaier, MethyQESD, a robust and
fast method for quantitative methylation analyses in HNPCC diagnostics using
formalin-ﬁxed and paraﬃn-embedded tissue samples. Lab Invest, 88 (12), 1367–
1375, 2008.
W. I. Beveridge, L. H. Sobin, International histological classiﬁcation of tumours of
domestic animals. introduction. Bull World Health Organ, 50 (1-2), 1–6, 1974.
K. P. L. Bhat, V. Balasubramaniyan, B. Vaillant, R. Ezhilarasan, K. Hummelink,
F. Hollingsworth, K. Wani, L. Heathcock, J. D. James, L. D. Goodman, S. Conroy,
L. Long, N. Lelic, S. Wang, J. Gumin, D. Raj, Y. Kodama, A. Raghunathan,
A. Olar, K. Joshi, C. E. Pelloski, A. Heimberger, S. H. Kim, D. P. Cahill, G. Rao,
W. F. A. Den Dunnen, H. W. G. M. Boddeke, H. S. Phillips, I. Nakano, F. F. Lang,
H. Colman, E. P. Sulman, K. Aldape, Mesenchymal diﬀerentiation mediated by
NF-κB promotes radiation resistance in glioblastoma. Cancer Cell, 24 (3), 331–
346, 2013.
R. Bonavia, M.-d.-M. Inda, W. K. Cavenee, F. B. Furnari, Heterogeneity mainte-
nance in glioblastoma: a social network. Cancer Res, 71 (12), 4055–60, 2011.
B. Campos, F.-S. Centner, J. L. Bermejo, R. Ali, K. Dorsch, F. Wan, J. Felsberg,
R. Ahmadi, N. Grabe, G. Reifenberger, A. Unterberg, J. Burhenne, C. C. Herold-
Mende, Aberrant expression of retinoic acid signaling molecules inﬂuences patient
survival in astrocytic gliomas. Am J Pathol, 178 (5), 1953–64, 2011.
B. Campos, F. Wan, M. Farhadi, A. Ernst, F. Zeppernick, K. E. Tagscherer, R. Ah-
madi, J. Lohr, C. Dictus, G. Gdynia, S. E. Combs, V. Goidts, B. M. Helmke,
V. Eckstein, W. Roth, P. Beckhove, P. Lichter, A. Unterberg, B. Radlwimmer,
C. Herold-Mende, Diﬀerentiation therapy exerts antitumor eﬀects on stem-like
glioma cells. Clin Cancer Res, 16 (10), 2715–2728, 2010.
M. Candolﬁ, J. F. Curtin, W. S. Nichols, A. G. Muhammad, G. D. King, G. E.
Pluhar, E. A. McNiel, J. R. Ohlfest, A. B. Freese, P. F. Moore, J. Lerner, P. R.
Lowenstein, M. G. Castro, Intracranial glioblastoma models in preclinical neuro-
oncology: neuropathological characterization and tumor progression. J Neuroon-
col, 85 (2), 133–148, 2007.
80
Bibliography
S. A. Choi, J. Y. Lee, J. H. Phi, K.-C. Wang, C.-K. Park, S.-H. Park, S.-K. Kim,
Identiﬁcation of brain tumour initiating cells using the stem cell marker aldehyde
dehydrogenase. Eur J Cancer, 50 (1), 137–49, 2014.
J. P. Chute, G. G. Muramoto, J. Whitesides, M. Colvin, R. Saﬁ, N. J. Chao, D. P.
McDonnell, Inhibition of aldehyde dehydrogenase and retinoid signaling induces
the expansion of human hematopoietic stem cells. Proc Natl Acad Sci U S A,
103 (31), 11707–11712, 2006.
C. A. Cornil, G. F. Ball, J. Balthazart, Rapid control of male typical behaviors by
brain-derived estrogens. Front Neuroendocrinol, 33 (4), 425–446, 2012.
P. Dalerba, R. W. Cho, M. F. Clarke, Cancer stem cells: models and concepts. Annu
Rev Med, 58, 267–284, 2007.
B. W. Davis, E. A. Ostrander, Domestic dogs and cancer research: a breed-based
genomics approach. ILAR J, 55 (1), 59–68, 2014.
G. J. De Vries, E. F. Rissman, R. B. Simerly, L.-Y. Yang, E. M. Scordalakes, C. J.
Auger, A. Swain, R. Lovell-Badge, P. S. Burgoyne, A. P. Arnold, A model system
for study of sex chromosome eﬀects on sexually dimorphic neural and behavioral
traits. J Neurosci, 22 (20), 9005–9014, 2002.
G. L. Defer, H. Adle-Biassette, F. Ricolﬁ, L. Martin, F. J. Authier, C. Chomienne,
L. Degos, J. D. Degos, All-trans retinoic acid in relapsing malignant gliomas: clin-
ical and radiological stabilization associated with the appearance of intratumoral
calciﬁcations. J Neurooncol, 34 (2), 169–177, 1997.
K. M. Dhandapani, D. W. Brann, Estrogen-astrocyte interactions: implications for
neuroprotection. BMC Neurosci, 3, 6, 2002.
A. C. Diserens, N. de Tribolet, A. Martin-Achard, A. C. Gaide, J. F. Schnegg,
S. Carrel, Characterization of an established human malignant glioma cell line:
LN18. Acta Neuropathol, 53 (1), 21–28, 1981.
G. Duester, F. A. Mic, A. Molotkov, Cytosolic retinoid dehydrogenases govern
ubiquitous metabolism of retinol to retinaldehyde followed by tissue-speciﬁc
metabolism to retinoic acid. Chem Biol Interact, 143-144, 201–210, 2003.
V. Dupé, N. Matt, J.-M. Garnier, P. Chambon, M. Mark, N. B. Ghyselinck, A
newborn lethal defect due to inactivation of retinaldehyde dehydrogenase type
3 is prevented by maternal retinoic acid treatment. Proc Natl Acad Sci U S A,
100 (24), 14036–14041, 2003.
D. I. Eneanya, J. R. Bianchine, D. O. Duran, B. D. Andresen, The actions of
metabolic fate of disulﬁram. Annu Rev Pharmacol Toxicol, 21, 575–96, 1981.
81
Bibliography
S. A. Erich, G. R. Rutteman, E. Teske, Causes of death and the impact of histiocytic
sarcoma on the life expectancy of the dutch population of bernese mountain dogs
and ﬂat-coated retrievers. Vet J, 198 (3), 678–683, 2013.
B. Fazi, A. Felsani, L. Grassi, A. Moles, D. D’Andrea, N. Toschi, D. Sicari, P. De
Bonis, C. Anile, M. G. Guerrisi, E. Luca, M. G. Farace, G. Maira, S. A. Ciafré,
A. Mangiola, The transcriptome and mirnome proﬁling of glioblastoma tissues
and peritumoral regions highlights molecular pathways shared by tumors and
surrounding areas and reveals diﬀerences between short-term and long-term sur-
vivors. Oncotarget, 2015.
M. J. Felini, A. F. Olshan, J. C. Schroeder, S. E. Carozza, R. Miike, T. Rice,
M. Wrensch, Reproductive factors and hormone use and risk of adult gliomas.
Cancer Causes Control, 20 (1), 87–96, 2009.
P. A. Flecknell, M. Mitchell, Midazolam and fentanyl-ﬂuanisone: assessment of
anaesthetic eﬀects in laboratory rodents and rabbits. Lab Anim, 18 (2), 143–146,
1984.
C. Ginestier, M. H. Hur, E. Charafe-Jauﬀret, F. Monville, J. Dutcher, M. Brown,
J. Jacquemier, P. Viens, C. G. Kleer, S. Liu, A. Schott, D. Hayes, D. Birnbaum,
M. S. Wicha, G. Dontu, ALDH1 is a marker of normal and malignant human
mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell,
1 (5), 555–67, 2007.
C. Ginestier, J. Wicinski, N. Cervera, F. Monville, P. Finetti, F. Bertucci, M. S.
Wicha, D. Birnbaum, E. Charafe-Jauﬀret, Retinoid signaling regulates breast can-
cer stem cell diﬀerentiation. Cell Cycle, 8 (20), 3297–3302, 2009.
C. J. Green, Neuroleptanalgesic drug combinations in the anaesthetic management
of small laboratory animals. Lab Anim, 9 (3), 161–178, 1975.
X. Guan, J. Vengoechea, S. Zheng, A. E. Sloan, Y. Chen, D. J. Brat, B. P. O’Neill,
J. de Groot, S. Yust-Katz, W.-K. A. Yung, M. L. Cohen, K. D. Aldape, S. Rosen-
feld, R. G. W. Verhaak, J. S. Barnholtz-Sloan, Molecular subtypes of glioblastoma
are relevant to lower grade glioma. PLoS One, 9 (3), e91216, 2014.
K. Hansen, C. Khanna, Spontaneous and genetically engineered animal models; use
in preclinical cancer drug development. Eur J Cancer, 40 (6), 858–880, 2004.
E. E. Hatch, M. S. Linet, J. Zhang, H. A. Fine, W. R. Shapiro, R. G. Selker, P. M.
Black, P. D. Inskip, Reproductive and hormonal factors and risk of brain tumors
in adult females. Int J Cancer, 114 (5), 797–805, 2005.
P. Hau, R. Stupp, M. E. Hegi, MGMT methylation status: the advent of stratiﬁed
therapy in glioblastoma? Dis Markers, 23 (1-2), 97–104, 2007.
82
Bibliography
H. M. Hayes, W. Priester, Jr, T. W. Pendergrass, Occurrence of nervous-tissue
tumors in cattle, horses, cats and dogs. Int J Cancer, 15 (1), 39–47, 1975.
M. E. Hegi, A.-C. Diserens, S. Godard, P.-Y. Dietrich, L. Regli, S. Ostermann,
P. Otten, G. Van Melle, N. de Tribolet, R. Stupp, Clinical trial substantiates the
predictive value of o6 -methylguanine-dna methyltransferase promoter methyla-
tion in glioblastoma patients treated with temozolomide. Clin Cancer Res, 10 (6),
1871–1874, 2004.
M. E. Hegi, L. Liu, J. G. Herman, R. Stupp, W. Wick, M. Weller, M. P. Mehta,
M. R. Gilbert, Correlation of o6 -methylguanine methyltransferase (MGMT) pro-
moter methylation with clinical outcomes in glioblastoma and clinical strategies
to modulate MGMT activity. J Clin Oncol, 26 (25), 4189–99, 2008.
J. Hilton, Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210
leukemia. Cancer Res, 44 (11), 5156–5160, 1984.
E. H. Huang, M. J. Hynes, T. Zhang, C. Ginestier, G. Dontu, H. Appelman, J. Z.
Fields, M. S. Wicha, B. M. Boman, Aldehyde dehydrogenase 1 is a marker for nor-
mal and malignant human colonic stem cells (SC) and tracks SC overpopulation
during colon tumorigenesis. Cancer Res, 69 (8), 3382–9, 2009.
B. L. Isfoss, B. Holmqvist, H. Jernström, P. Alm, H. Olsson, Women with familial
risk for breast cancer have an increased frequency of aldehyde dehydrogenase
expressing cells in breast ductules. BMC Clin Pathol, 13 (1), 28, 2013.
A. Iwanami, B. Gini, C. Zanca, T. Matsutani, A. Assuncao, A. Nael, J. Dang,
H. Yang, S. Zhu, J. Kohyama, I. Kitabayashi, W. K. Cavenee, T. F. Cloughesy,
F. B. Furnari, M. Nakamura, Y. Toyama, H. Okano, P. S. Mischel, Pml medi-
ates glioblastoma resistance to mammalian target of rapamycin (mtor)-targeted
therapies. Proc Natl Acad Sci U S A, 110 (11), 4339–4344, 2013.
B. Jackson, C. Brocker, D. C. Thompson, W. Black, K. Vasiliou, D. W. Nebert,
V. Vasiliou, Update on the aldehyde dehydrogenase gene (ALDH) superfamily.
Hum Genomics, 5 (4), 283–303, 2011.
R. J. Jones, J. P. Barber, M. S. Vala, M. I. Collector, S. H. Kaufmann, S. M.
Ludeman, O. M. Colvin, J. Hilton, Assessment of aldehyde dehydrogenase in
viable cells. Blood, 85 (10), 2742–2746, 1995.
S. E. Kaba, A. P. Kyritsis, C. Conrad, M. J. Gleason, R. Newman, V. A. Levin,
W. K. Yung, The treatment of recurrent cerebral gliomas with all-trans-retinoic
acid (tretinoin). J Neurooncol, 34 (2), 145–151, 1997.
E. K. Karlsson, I. Baranowska, C. M. Wade, N. H. C. Salmon Hillbertz, M. C. Zody,
N. Anderson, T. M. Biagi, N. Patterson, G. R. Pielberg, E. J. Kulbokas, 3rd, K. E.
Comstock, E. T. Keller, J. P. Mesirov, H. von Euler, O. Kämpe, A. Hedhammar,
83
Bibliography
E. S. Lander, G. Andersson, L. Andersson, K. Lindblad-Toh, Eﬃcient mapping
of mendelian traits in dogs through genome-wide association. Nat Genet, 39 (11),
1321–1328, 2007.
R. E. Kast, G. Karpel-Massler, M.-E. Halatsch, CUSP9* treatment protocol for
recurrent glioblastoma: aprepitant, artesunate, auranoﬁn, captopril, celecoxib,
disulﬁram, itraconazole, ritonavir, sertraline augmenting continuous low dose
temozolomide. Oncotarget, 5 (18), 8052–82, 2014.
Y. Kirihara, M. Takechi, K. Kurosaki, Y. Kobayashi, Y. Saito, T. Takeuchi, Anes-
thetic eﬀects of a three-drugs mixture-comparison of administrative routes and
antagonistic eﬀects of atipamezole in mice. Exp Anim, 2014.
M. A. Lane, S. J. Bailey, Role of retinoid signalling in the adult brain. Prog Neurobiol,
75 (4), 275–293, 2005.
T. Li, Y. Su, Y. Mei, Q. Leng, B. Leng, Z. Liu, S. A. Stass, F. Jiang, ALDH1A1 is a
marker for malignant prostate stem cells and predictor of prostate cancer patients’
outcome. Lab Invest, 90 (2), 234–244, 2010.
J. Liu, P. Wang, X. Zhang, W. Zhang, G. Gu, Eﬀects of diﬀerent concentration
and duration time of isoﬂurane on acute and long-term neurocognitive function
of young adult c57bl/6 mouse. Int J Clin Exp Pathol, 7 (9), 5828–5836, 2014a.
Y. Liu, D.-L. Lv, J.-J. Duan, S.-L. Xu, J.-F. Zhang, X.-J. Yang, X. Zhang, Y.-H.
Cui, X.-W. Bian, S.-C. Yu, ALDH1A1 expression correlates with clinicopathologic
features and poor prognosis of breast cancer patients: a systematic review and
meta-analysis. BMC Cancer, 14, 444, 2014b.
T. W. Loo, D. M. Clarke, Blockage of drug resistance in vitro by disulﬁram, a drug
used to treat alcoholism. J Natl Cancer Inst, 92 (11), 898–902, 2000.
M. López-Lázaro, Stem cell division theory of cancer. Cell Cycle, pages 2547–2548,
2015.
D. N. Louis, H. Ohgaki, O. D. Wiestler, W. K. Cavenee (Editors), WHO Clas-
siﬁcation of Tumours of the Central Nervous System. International Agency for
Research on Cancer (IARC), 69008 Lyon, France, 4th edition, 2007.
I. Ma, A. L. Allan, The role of human aldehyde dehydrogenase in normal and cancer
stem cells. Stem Cell Rev, 7 (2), 292–306, 2011.
P. Mao, K. Joshi, J. Li, S.-H. Kim, P. Li, L. Santana-Santos, S. Luthra, U. R.
Chandran, P. V. Benos, L. Smith, M. Wang, B. Hu, S.-Y. Cheng, R. W. Sobol,
I. Nakano, Mesenchymal glioma stem cells are maintained by activated glycolytic
metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci U S A,
110 (21), 8644–9, 2013.
84
Bibliography
P. Marcato, C. A. Dean, C. A. Giacomantonio, P. W. Lee, Aldehyde dehydrogenase:
its role as a cancer stem cell marker comes down to the speciﬁc isoform. Cell
Cycle, 10 (9), 1378–84, 2011a.
P. Marcato, C. A. Dean, R.-Z. Liu, K. M. Coyle, M. Bydoun, M. Wallace,
D. Clements, C. Turner, E. G. Mathenge, S. A. Gujar, C. A. Giacomantonio,
J. R. Mackey, R. Godbout, P. W. K. Lee, Aldehyde dehydrogenase 1a3 inﬂuences
breast cancer progression via diﬀerential retinoic acid signaling. Mol Oncol, 9 (1),
17–31, 2015.
P. Marcato, C. A. Dean, D. Pan, R. Araslanova, M. Gillis, M. Joshi, L. Helyer,
L. Pan, A. Leidal, S. Gujar, C. A. Giacomantonio, P. W. K. Lee, Aldehyde
dehydrogenase activity of breast cancer stem cells is primarily due to isoform
ALDH1A3 and its expression is predictive of metastasis. Stem Cells, 29 (1), 32–
45, 2011b.
S. A. Marchitti, C. Brocker, D. Stagos, V. Vasiliou, Non-p450 aldehyde oxidizing en-
zymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol,
4 (6), 697–720, 2008.
L. C. Matsumiya, R. E. Sorge, S. G. Sotocinal, J. M. Tabaka, J. S. Wieskopf,
A. Zaloum, O. D. King, J. S. Mogil, Using the mouse grimace scale to reevaluate
the eﬃcacy of postoperative analgesics in laboratory mice. J Am Assoc Lab Anim
Sci, 51 (1), 42–49, 2012.
L. D. McCullough, K. Blizzard, E. R. Simpson, O. K. Oz, P. D. Hurn, Aromatase cy-
tochrome p450 and extragonadal estrogen play a role in ischemic neuroprotection.
J Neurosci, 23 (25), 8701–8705, 2003.
M. M. Mrugala, L. K. Crew, J. R. Fink, A. M. Spence, Carboplatin and bevacizumab
for recurrent malignant glioma. Oncol Lett, 4 (5), 1082–1086, 2012.
G. G. Muramoto, J. L. Russell, R. Saﬁ, A. B. Salter, H. A. Himburg, P. Daher,
S. K. Meadows, P. Doan, R. W. Storms, N. J. Chao, D. P. McDonnell, J. P.
Chute, Inhibition of aldehyde dehydrogenase expands hematopoietic stem cells
with radioprotective capacity. Stem Cells, 28 (3), 523–534, 2010.
I. Nakano, Stem cell signature in glioblastoma: therapeutic development for a mov-
ing target. J Neurosurg, pages 1–7, 2014.
W. Ni, L. Luo, Z. Ping, H. P. Yuan, X. D. Zhao, W. Xu, Prognostic value of
ALDH1A3 promoter methylation in glioblastoma: a single center experience in
western china. Asian Pac J Cancer Prev, 16 (2), 591–4, 2015.
S. Nobusawa, T. Watanabe, P. Kleihues, H. Ohgaki, IDH1 mutations as molecu-
lar signature and predictive factor of secondary glioblastomas. Clin Cancer Res,
15 (19), 6002–6007, 2009.
85
Bibliography
M. R. Olin, G. E. Pluhar, B. M. Andersen, R. Shaver, N. N. Waldron, C. L. Moertel,
Victory and defeat in the induction of a therapeutic response through vaccine
therapy for human and canine brain tumors: a review of the state of the art. Crit
Rev Immunol, 34 (5), 399–432, 2014.
T. Ozawa, C. D. James, Establishing intracranial brain tumor xenografts with sub-
sequent analysis of tumor growth and response to therapy using bioluminescence
imaging. J Vis Exp, (41), 2010.
J. Pallud, E. Audureau, G. Noel, R. Corns, E. Lechapt-Zalcman, J. Duntze,
V. Pavlov, J. Guyotat, P. D. Hieu, P.-J. Le Reste, T. Faillot, C.-F. Litre,
N. Desse, A. Petit, E. Emery, J. Voirin, J. Peltier, F. Caire, J.-R. Vignes, J.-
L. Barat, O. Langlois, E. Dezamis, E. Parraga, M. Zanello, E. Nader, M. Lefranc,
L. Bauchet, B. Devaux, P. Menei, P. Metellus, C. , Long-term results of carmustine
wafer implantation for newly diagnosed glioblastomas: a controlled propensity-
matched analysis of a french multicenter cohort. Neuro Oncol, 2015.
A. C. Palmer, Comparative aspects of tumours of the central nervous system in the
dog. Proc R Soc Med, 69 (1), 49–51, 1976.
C. Y. Park, D. Tseng, I. L. Weissman, Cancer stem cell-directed therapies: recent
data from the laboratory and clinic. Mol Ther, 17 (2), 219–230, 2009.
J. M. Petrosino, D. Disilvestro, O. Ziouzenkova, Aldehyde dehydrogenase 1a1: friend
or foe to female metabolism? Nutrients, 6 (3), 950–73, 2014.
S. Phuphanich, C. Scott, A. J. Fischbach, C. Langer, W. K. Yung, All-trans-retinoic
acid: a phase ii radiation therapy oncology group study (rtog 91-13) in patients
with recurrent malignant astrocytoma. J Neurooncol, 34 (2), 193–200, 1997.
R. J. Plunkett, A. Lis, T. A. Barone, M. D. Fronckowiak, S. J. Greenberg, Hormonal
eﬀects on glioblastoma multiforme in the nude rat model. J Neurosurg, 90 (6),
1072–1077, 1999.
V. Quillien, A. Lavenu, L. Karayan-Tapon, C. Carpentier, M. Labussière, T. Les-
imple, O. Chinot, M. Wager, J. Honnorat, S. Saikali, F. Fina, M. San-
son, D. Figarella-Branger, Comparative assessment of 5 methods (methylation-
speciﬁc polymerase chain reaction, methylight, pyrosequencing, methylation-
sensitive high-resolution melting, and immunohistochemistry) to analyze O6 -
methylguanine-DNA methyltransferase in a series of 100 glioblastoma patients.
Cancer, 118 (17), 4201–4211, 2012.
D. Raha, T. R. Wilson, J. Peng, D. Peterson, P. Yue, M. Evangelista, C. Wilson,
M. Merchant, J. Settleman, The cancer stem cell marker aldehyde dehydrogenase
is required to maintain a drug-tolerant tumor cell subpopulation. Cancer Res,
74 (13), 3579–90, 2014.
86
Bibliography
M. Rasper, A. Schäfer, G. Piontek, J. Teufel, G. Brockhoﬀ, F. Ringel, S. Heindl,
C. Zimmer, J. Schlegel, Aldehyde dehydrogenase 1 positive glioblastoma cells show
brain tumor stem cell capacity. Neuro Oncol, 12 (10), 1024–33, 2010.
D. Sano, J. N. Myers, Xenograft models of head and neck cancers. Head Neck Oncol,
1, 32, 2009.
A. Schäfer, J. Teufel, F. Ringel, M. Bettstetter, I. Hoepner, M. Rasper, J. Gempt,
J. Koeritzer, F. Schmidt-Graf, B. Meyer, C. P. Beier, J. Schlegel, Aldehyde de-
hydrogenase 1A1–a new mediator of resistance to temozolomide in glioblastoma.
Neuro Oncol, 14 (12), 1452–64, 2012.
N. O. Schmidt, M. Ziu, G. Carrabba, C. Giussani, L. Bello, Y. Sun, K. Schmidt,
M. Albert, P. M. Black, R. S. Carroll, Antiangiogenic therapy by local intrac-
erebral microinfusion improves treatment eﬃciency and survival in an orthotopic
human glioblastoma model. Clin Cancer Res, 10 (4), 1255–1262, 2004.
S. K. Singh, I. D. Clarke, M. Terasaki, V. E. Bonn, C. Hawkins, J. Squire, P. B.
Dirks, Identiﬁcation of a cancer stem cell in human brain tumors. Cancer Res,
63 (18), 5821–8, 2003.
N. R. Smoll, K. Schaller, O. P. Gautschi, Long-term survival of patients with glioblas-
toma multiforme (GBM). J Clin Neurosci, 20 (5), 670–675, 2013.
J. M. Snyder, F. S. Shofer, T. J. Van Winkle, C. Massicotte, Canine intracranial
primary neoplasia: 173 cases (1986-2003). J Vet Intern Med, 20 (3), 669–675,
2006.
R. B. Song, C. H. Vite, C. W. Bradley, J. R. Cross, Postmortem evaluation of 435
cases of intracranial neoplasia in dogs and relationship of neoplasm with breed,
age, and body weight. J Vet Intern Med, 27 (5), 1143–1152, 2013.
B. Stangeland, A. A. Mughal, Z. Grieg, C. J. Sandberg, M. Joel, S. Nygård, T. Mel-
ing, W. Murrell, E. O. Vik Mo, I. A. Langmoen, Combined expressional analysis,
bioinformatics and targeted proteomics identify new potential therapeutic targets
in glioblastoma stem cells. Oncotarget, 2015.
G. Stoica, G. Lungu, H. Martini-Stoica, S. Waghela, J. Levine, R. Smith, 3rd,
Identiﬁcation of cancer stem cells in dog glioblastoma. Vet Pathol, 46 (3), 391–
406, 2009.
T. Strojnik, R. Kavalar, T. A. Barone, R. J. Plunkett, Experimental model and
immunohistochemical comparison of u87 human glioblastoma cell xenografts on
the chicken chorioallantoic membrane and in rat brains. Anticancer Res, 30 (12),
4851–4860, 2010.
J. B. Stubbs, R. H. Frankel, K. Schultz, I. Crocker, D. Dillehay, J. J. Olson, Pre-
clinical evaluation of a novel device for delivering brachytherapy to the margins
of resected brain tumor cavities. J Neurosurg, 96 (2), 335–343, 2002.
87
Bibliography
R. Stupp, M. E. Hegi, W. P. Mason, M. J. van den Bent, M. J. Taphoorn, R. C.
Janzer, S. K. Ludwin, A. Allgeier, B. Fisher, K. Belanger, P. Hau, A. A. Bran-
des, J. Gijtenbeek, C. Marosi, C. J. Vecht, K. Mokhtari, P. Wesseling, S. Villa,
E. Eisenhauer, T. Gorlia, M. Weller, D. Lacombe, J. G. Cairncross, R. O. Mi-
rimanoﬀ, Eﬀects of radiotherapy with concomitant and adjuvant temozolomide
versus radiotherapy alone on survival in glioblastoma in a randomised phase III
study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol, 10 (5), 459–66,
2009.
R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. B. Taphoorn,
K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer,
S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, E. Eisenhauer,
R. O. Mirimanoﬀ, Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med, 352 (10), 987–96, 2005.
M. E. Sughrue, T. Sheean, P. A. Bonney, A. J. Maurer, C. Teo, Aggressive re-
peat surgery for focally recurrent primary glioblastoma: outcomes and theoretical
framework. Neurosurg Focus, 38 (3), E11, 2015.
C. Sun, D. Zhao, X. Dai, J. Chen, X. Rong, H. Wang, A. Wang, M. Li, J. Dong,
Q. Huang, Q. Lan, Fusion of cancer stem cells and mesenchymal stem cells con-
tributes to glioma neovascularization. Oncol Rep, 34 (4), 2022–2030, 2015.
T. Sun, N. M. Warrington, J. Luo, M. D. Brooks, S. Dahiya, S. C. Snyder, R. Sen-
gupta, J. B. Rubin, Sexually dimorphic rb inactivation underlies mesenchymal
glioblastoma prevalence in males. J Clin Invest, 124 (9), 4123–4133, 2014.
A. Suzuki, P. Leland, H. Kobayashi, P. L. Choyke, E. M. Jagoda, T. Inoue, B. H.
Joshi, R. K. Puri, Analysis of biodistribution of intracranially infused radiolabeled
interleukin-13 receptor-targeted immunotoxin IL-13PE by SPECT/CT in an or-
thotopic mouse model of human glioma. J Nucl Med, 55 (8), 1323–1329, 2014.
T. Szatmári, K. Lumniczky, S. Désaknai, S. Trajcevski, E. J. Hídvégi, H. Hamada,
G. Sáfrány, Detailed characterization of the mouse glioma 261 tumor model for
experimental glioblastoma therapy. Cancer Sci, 97 (6), 546–553, 2006.
M. Uhlén, E. Björling, C. Agaton, C. A.-K. Szigyarto, B. Amini, E. Andersen, A.-C.
Andersson, P. Angelidou, A. Asplund, C. Asplund, L. Berglund, K. Bergström,
H. Brumer, D. Cerjan, M. Ekström, A. Elobeid, C. Eriksson, L. Fagerberg,
R. Falk, J. Fall, M. Forsberg, M. G. Björklund, K. Gumbel, A. Halimi, I. Hallin,
C. Hamsten, M. Hansson, M. Hedhammar, G. Hercules, C. Kampf, K. Larsson,
M. Lindskog, W. Lodewyckx, J. Lund, J. Lundeberg, K. Magnusson, E. Malm,
P. Nilsson, J. Odling, P. Oksvold, I. Olsson, E. Oster, J. Ottosson, L. Paavilainen,
A. Persson, R. Rimini, J. Rockberg, M. Runeson, A. Sivertsson, A. Sköllermo,
J. Steen, M. Stenvall, F. Sterky, S. Strömberg, M. Sundberg, H. Tegel, S. Tourle,
E. Wahlund, A. Waldén, J. Wan, H. Wernérus, J. Westberg, K. Wester, U. Wretha-
gen, L. L. Xu, S. Hober, F. Pontén, A human protein atlas for normal and cancer
88
Bibliography
tissues based on antibody proteomics. Mol Cell Proteomics, 4 (12), 1920–1932,
2005.
V. Vasiliou, D. W. Nebert, Analysis and update of the human aldehyde dehydroge-
nase (aldh) gene family. Hum Genomics, 2 (2), 138–43, 2005.
R. G. W. Verhaak, K. A. Hoadley, E. Purdom, V. Wang, Y. Qi, M. D. Wilkerson,
C. R. Miller, L. Ding, T. Golub, J. P. Mesirov, G. Alexe, M. Lawrence, M. O’Kelly,
P. Tamayo, B. A. Weir, S. Gabriel, W. Winckler, S. Gupta, L. Jakkula, H. S. Feiler,
J. G. Hodgson, C. D. James, J. N. Sarkaria, C. Brennan, A. Kahn, P. T. Spellman,
R. K. Wilson, T. P. Speed, J. W. Gray, M. Meyerson, G. Getz, C. M. Perou,
D. N. Hayes, C. G. A. R. N. , Integrated genomic analysis identiﬁes clinically
relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA,
IDH1, EGFR, and NF1. Cancer Cell, 17 (1), 98–110, 2010.
K. Vigneswaran, S. Neill, C. G. Hadjipanayis, Beyond the world health organiza-
tion grading of inﬁltrating gliomas: advances in the molecular genetics of glioma
classiﬁcation. Ann Transl Med, 3 (7), 95, 2015.
G. H. Vince, M. Bendszus, T. Schweitzer, R. H. Goldbrunner, S. Hildebrandt,
J. Tilgner, R. Klein, L. Solymosi, J. Christian Tonn, K. Roosen, Spontaneous
regression of experimental gliomas–an immunohistochemical and MRI study of
the C6 glioma spheroid implantation model. Exp Neurol, 190 (2), 478–485, 2004.
K. Wang, X. Wu, J. Wang, J. Huang, Cancer stem cell theory: therapeutic impli-
cations for nanomedicine. Int J Nanomedicine, 8, 899–908, 2013.
W. A. Weiss, M. Israel, C. Cobbs, E. Holland, C. D. James, D. N. Louis, C. Marks,
A. I. McClatchey, T. Roberts, T. Van Dyke, C. Wetmore, I.-M. Chiu, M. Giovan-
nini, A. Guha, R. J. Higgins, S. Marino, I. Radovanovic, K. Reilly, K. Aldape,
Neuropathology of genetically engineered mice: consensus report and recommen-
dations from an international forum. Oncogene, 21 (49), 7453–7463, 2002.
C. Wismeth, P. Hau, K. Fabel, U. Baumgart, B. Hirschmann, H. Koch, T. Jauch,
O. Grauer, L. Drechsel, A. Brawanski, U. Bogdahn, A. Steinbrecher, Maintenance
therapy with 13-cis retinoid acid in high-grade glioma at complete response after
ﬁrst-line multimodal therapy–a phase-ii study. J Neurooncol, 68 (1), 79–86, 2004.
T.-W. Wu, J. M. Wang, S. Chen, R. D. Brinton, 17beta-estradiol induced ca2+
inﬂux via l-type calcium channels activates the src/erk/cyclic-amp response el-
ement binding protein signal pathway and bcl-2 expression in rat hippocampal
neurons: a potential initiation mechanism for estrogen-induced neuroprotection.
Neuroscience, 135 (1), 59–72, 2005.
W. Xiong, M. Candolﬁ, C. Liu, A. K. M. G. Muhammad, K. Yagiz, M. Puntel,
P. F. Moore, J. Avalos, J. D. Young, D. Khan, R. Donelson, G. E. Pluhar, J. R.
Ohlfest, K. Wawrowsky, P. R. Lowenstein, M. G. Castro, Human ﬂt3l generates
89
Bibliography
dendritic cells from canine peripheral blood precursors: implications for a dog
glioma clinical trial. PLoS One, 5 (6), e11074, 2010.
N. Xu, M. M. Shao, H. T. Zhang, M. S. Jin, Y. Dong, R. J. Ou, H. M. Wang, A. P.
Shi, Aldehyde dehydrogenase 1 (ALDH1) expression is associated with a poor
prognosis of bladder cancer. Cancer Epidemiol, 39 (3), 375–81, 2015a.
S.-L. Xu, S. Liu, W. Cui, Y. Shi, Q. Liu, J.-J. Duan, S.-C. Yu, X. Zhang, Y.-H.
Cui, H.-F. Kung, X.-W. Bian, Aldehyde dehydrogenase 1A1 circumscribes high
invasive glioma cells and predicts poor prognosis. Am J Cancer Res, 5 (4), 1471–
1483, 2015b.
J. S. Yakisich, A. Sidén, P. Eneroth, M. Cruz, Disulﬁram is a potent in vitro inhibitor
of dna topoisomerases. Biochem Biophys Res Commun, 289 (2), 586–590, 2001.
S. Yamada, V. Khankaldyyan, X. Bu, A. Suzuki, I. Gonzalez-Gomez, K. Takahashi,
J. G. McComb, W. E. Laug, A method to accurately inject tumor cells into the
caudate/putamen nuclei of the mouse brain. Tokai J Exp Clin Med, 29 (4), 167–73,
2004.
Y. Yanagawa, J. C. Chen, L. C. Hsu, A. Yoshida, The transcriptional regulation of
human aldehyde dehydrogenase i gene. the structural and functional analysis of
the promoter. J Biol Chem, 270 (29), 17521–17527, 1995.
L.-c. Yang, Q.-G. Zhang, C.-f. Zhou, F. Yang, Y.-d. Zhang, R.-m. Wang, D. W.
Brann, Extranuclear estrogen receptors mediate the neuroprotective eﬀects of es-
trogen in the rat hippocampus. PLoS One, 5 (5), e9851, 2010.
J. Ye, G. Coulouris, I. Zaretskaya, I. Cutcutache, S. Rozen, T. L. Madden, Primer-
blast: a tool to design target-speciﬁc primers for polymerase chain reaction. BMC
Bioinformatics, 13, 134, 2012.
D. York, R. J. Higgins, R. A. LeCouteur, A. N. Wolfe, R. Grahn, N. Olby, M. Camp-
bell, P. J. Dickinson, TP53 mutations in canine brain tumors. Vet Pathol, 49 (5),
796–801, 2012.
W. Zhang, W. Yan, G. You, Z. Bao, Y. Wang, Y. Liu, Y. You, T. Jiang, Genome-
wide DNA methylation proﬁling identiﬁes ALDH1A3 promoter methylation as
a prognostic predictor in G-CIMP- primary glioblastoma. Cancer Lett, 328 (1),
120–5, 2013.
D. Zhao, Y. Mo, M.-T. Li, S.-W. Zou, Z.-L. Cheng, Y.-P. Sun, Y. Xiong, K.-L.
Guan, Q.-Y. Lei, Notch-induced aldehyde dehydrogenase 1a1 deacetylation pro-
motes breast cancer stem cells. J Clin Invest, 2014.
L. Zhao, R. D. Brinton, Estrogen receptor alpha and beta diﬀerentially regulate
intracellular ca(2+) dynamics leading to erk phosphorylation and estrogen neu-
roprotection in hippocampal neurons. Brain Res, 1172, 48–59, 2007.
90
Bibliography
C. J. Zuurbier, A. Koeman, S. M. Houten, M. W. Hollmann, W. J. Florijn, Optimiz-
ing anesthetic regimen for surgery in mice through minimization of hemodynamic,
metabolic, and inﬂammatory perturbations. Exp Biol Med (Maywood), 239 (6),
737–746, 2014.
91
10 Danksagung
Mein besonderer Dank geht an Herrn Prof. Dr. Kaspar Matiasek, der mir die Mög-
lichkeit gegeben hat in die spannende Welt der Neuropathologie hineinzutauchen.
Bei Herrn Prof. Dr. Jürgen Schlegel bedanke ich mich herzlich dafür, dass er mir
nicht nur sein Labor zu Verfügung gestellt hat, mir Geduld und Vertrauen während
der Zeit geschenkt hat, sondern auch immer dafür gesorgt hat, dass ich nicht unter
einer Brücke schlafen musste.
Ich danke Herrn Prof. Dr. Höﬂer, an dessen Institut ich diese Arbeit anfertigen
durfte.
Ich bedanke mich auch herzlich bei meinen Kolleginnen und Kollegen, für anregen-
de wissenschaftliche Diskussionen und unterhaltsame Stunden auch außerhalb des
Labors. Dabei sind Christine Grubmüller und Sandra Baur namentlich zu nennen,
die mich bei der Durchführung der RT-PCR und IHC tatkräftig unterstützt haben.
An Claire Delbridge geht mein Dank für Tee, Eis und Kuchen, sowie kritisches
Korrekturlesen, IHC-scoren,...
Ein Dank geht auch an Ebba Beller und Tobias Boeckh-Behrens für die humanen
und Anne Kluge für die murinen MRT Bilder. Katja Steiger hat mich tatkräftig
während der Anfertigung dieser Arbeit untersützt, ihr sind Farbe und Qualität der
Bilder zu verdanken.
Ich danke auch dem StaBLab Team der LMU München und besonders Felix Gün-
ther für den R-Kurs und die Beratung bei der statistsichen Auswertung.
Danke Eckhart, für die persönliche Unterstützung und für den LATEX-Support.
Zuletzt möchte ich mich bei meinen Eltern bedanken, die mich während des Stu-
diums durchgefüttert haben. Es ist auch ein Teil eures Verdienstes, dass diese Arbeit
fertig gestellt werden konnte.
92
